QUATERNARY TRYPTAMINES AND THEIR THERAPEUTIC USES

Abstract

The disclosure relates to compounds of formula (I): Among the substituents in a compound of formula (I), one of R.sub.4 and R.sub.5 is hydrogen and the other of R.sub.4 and R.sub.5 is OSC.sub.2Rs.sub.6. The disclosure relates to compounds of formula (II): Among the substituents in a compound of formula (II), R.sub.6 is a halogen chosen from F, Cl, Br, and I. The disclosure relates to compositions comprising a compound of formulas (I) or (II) and an excipient. The disclosure relates to pharmaceutical compositions comprising a therapeutically effective amount of a compound of formulas (I) or (II). The disclosure relates to therapeutic uses of compounds of formulas (I) or (II). The disclosure relates to compounds of formula (II), including 5-fluoro-N,N,N-trimethyltryptammonium iodide, 5-fluoro-N,N,N-triethyltryptammonium iodide, 5-fluoro-N,N,N-tri-n-propyltryptammonium iodide, 5-chloro-N,N,N-trimethyltrptammonium iodide, 5-chloro-N,N,N-triethyltryptammonium iodide, 5-bromo-N,N,N-triethyltryptammonium iodide, 5-bromo-N,N,N-tri-n-propyltryptammonium iodide, and 5-bromo-N,N,N-tri-n-propyltryptammonium iodide acetonitrile solvate and their crystalline forms and their compositions and uses.

##STR00001##

Claims

1. A quaternary amine compound of formula (I): ##STR00020## wherein: R.sub.1, R.sub.2, and R.sub.3 are each independently chosen from a C.sub.1-C.sub.6 alkyl or C.sub.2-C.sub.6 alkenyl; one of R.sub.4 and R.sub.5 is hydrogen and the other of R.sub.4 and R.sub.5 is OSO.sub.2R.sub.6; R.sub.6 is a C.sub.1-C.sub.6 alkyl or a substituted or unsubstituted aryl; R.sub.7, R.sub.8, and R.sub.9 are each independently hydrogen or C.sub.1-C.sub.6 alkyl; R.sub.10 is selected from hydrogen, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, halogen, hydroxy, OR.sub.6, OC(O)R.sub.6, OC(O)OR.sub.6, or OSO.sub.2R.sub.6; R.sub.11 is selected from hydrogen, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C(O)R.sub.6, C(O)OR.sub.6, or SO.sub.2R.sub.6; and X.sup. is a pharmaceutically acceptable anion.

2. A compound of formula (I) according to claim 1, wherein R.sub.4 is hydrogen and R.sub.5 is OSO.sub.2R.sub.6.

3. A compound of formula (I) according to claim 1, wherein R.sub.5 is hydrogen and R.sub.4 is OSO.sub.2R.sub.6.

4-20. (canceled)

21. A composition comprising, consisting essentially of, or consisting of a compound according to claim 1 and an excipient.

22. (canceled)

23. A pharmaceutical composition comprising, consisting essentially of, or consisting of a therapeutically effective amount of a compound according to claim 1, and a pharmaceutically acceptable excipient.

24. A composition comprising, consisting essentially of, or consisting of as a first active component: a compound according to claim 1; and as a second active component selected from (a) a serotonergic drug, (b) a purified psilocybin derivative, (c) one or two purified cannabinoids and (d) a purified terpene; and a pharmaceutically acceptable excipient.

25. A composition comprising, consisting essentially of, or consisting of as a first active component: a compound according to claim 1; and a second active component comprising an adrenergic drug or a dopaminergic drug; and a pharmaceutically acceptable excipient.

26. A composition comprising, consisting essentially of, or consisting of as a first active component: a compound according to claim 1; and a second active component comprising a purified monoamine oxidase inhibitor; and a pharmaceutically acceptable excipient.

27. A composition comprising, consisting essentially of, or consisting of as a first active component: a compound according to claim 1; and a second active component comprising a purified erinacine or a purified hericenone; and a pharmaceutically acceptable excipient.

28-35. (canceled)

36. A method of generating a dialkyltryptamine compound comprising contacting at least one compound according to claim 1 with an enzyme capable of nitrogen dealkylation.

37. The method of claim 36, wherein the enzyme comprises a CYP enzyme.

38. A method of generating a dialkyltryptamine compound in situ in a patient, comprising contacting at a compound according to claim 1 with an enzyme in the patient capable of nitrogen dealkylation.

39. The method of claim 38, wherein the enzyme comprises a CYP enzyme.

40-67. (canceled)

68. A composition comprising, consisting essentially of, or consisting of a compound according to claim 2 and an excipient.

69. A composition comprising, consisting essentially of, or consisting of a compound according to claim 3 and an excipient.

70. A pharmaceutical composition comprising, consisting essentially of, or consisting of a therapeutically effective amount of a compound according to claim 2 and a pharmaceutically acceptable excipient.

71. A pharmaceutical composition comprising, consisting essentially of, or consisting of a therapeutically effective amount of a compound according to claim 3 and a pharmaceutically acceptable excipient.

72. A composition comprising, consisting essentially of, or consisting of as a first active component: a compound according to claim 2; and as a second active component selected from (a) a serotonergic drug, (b) a purified psilocybin derivative, (c) one or two purified cannabinoids and (d) a purified terpene; and a pharmaceutically acceptable excipient.

73. A composition comprising, consisting essentially of, or consisting of as a first active component: a compound according to claim 3; and as a second active component selected from (a) a serotonergic drug, (b) a purified psilocybin derivative, (c) one or two purified cannabinoids and (d) a purified terpene; and a pharmaceutically acceptable excipient.

Description

DESCRIPTION OF THE FIGURES

[0048] FIG. 1 shows the molecular structure of crystalline 5-fluoro-N,N,N-trimethyltryptammonium (5-F-TMT) iodide, showing the atom labeling.

[0049] FIG. 2 shows a simulated x-ray powder diffraction (XRPD) of crystalline 5-F-TMT iodide from its single crystal data.

[0050] FIG. 3 shows the molecular structure of crystalline 5-fluoro-N,N,N-triethyltryptammonium (5-F-TET) iodide, showing the atom labeling.

[0051] FIG. 4 shows a simulated x-ray powder diffraction (XRPD) of crystalline 5-F-TET iodide from its single crystal data.

[0052] FIG. 5 shows the molecular structure of crystalline 5-fluoro-N,N,N-tri-n-propyltryptammonium (5-F-TPT) iodide, showing the atom labeling.

[0053] FIG. 6 shows a simulated x-ray powder diffraction (XRPD) of crystalline 5-F-TPT iodide from its single crystal data.

[0054] FIG. 7 shows the molecular structure of crystalline 5-chloro-N,N,N-trimethyltryptammonium (5-Cl-TMT) iodide, showing the atom labeling.

[0055] FIG. 8 shows a simulated x-ray powder diffraction (XRPD) of crystalline 5-Cl-TMT iodide from its single crystal data.

[0056] FIG. 9 shows the molecular structure of crystalline 5-chloro-N,N,N-triethyltryptammonium (5-Cl-TET) iodide, showing the atom labeling.

[0057] FIG. 10 shows a simulated x-ray powder diffraction (XRPD) of crystalline 5-Cl-TET iodide from its single crystal data.

[0058] FIG. 11 shows the molecular structure of crystalline 5-bromo-N,N,N-triethyltryptammonium (5-Br-TET) iodide, showing the atom labeling.

[0059] FIG. 12 shows a simulated x-ray powder diffraction (XRPD) of crystalline 5-Br-TET iodide from its single crystal data.

[0060] FIG. 13 shows the molecular structure of crystalline 5-bromo-N,N,N-tri-n-propyltryptammonium (5-Br-TPT) iodide, showing the atom labeling.

[0061] FIG. 14 shows a simulated x-ray powder diffraction (XRPD) of crystalline 5-Br-TPT iodide from its single crystal data.

[0062] FIG. 15 shows the molecular structure of crystalline 5-bromo-N,N,N-tri-n-propyltryptammonium (5-Br-TPT) iodide acetonitrile solvate, showing the atom labeling.

[0063] FIG. 16 shows a simulated x-ray powder diffraction (XRPD) of crystalline 5-Br-TPT iodide acetonitrile solvate from its single crystal data.

DETAILED DESCRIPTION

[0064] Compounds

[0065] This disclosure relates to quaternary amine compounds of formula (I):

##STR00005##

wherein: [0066] R.sub.1, R.sub.2, and R.sub.3 are each independently chosen from a C.sub.1-C.sub.6 alkyl or C.sub.2-C.sub.6 alkenyl; [0067] one of R.sub.4 and R.sub.5 is hydrogen and the other of R.sub.4 and R.sub.5 is OSO.sub.2R.sub.6; [0068] R.sub.6 is a C.sub.1-C.sub.6 alkyl or a substituted or unsubstituted aryl; [0069] R.sub.7, R.sub.8, and R.sub.9 are each independently hydrogen or C.sub.1-C.sub.6 alkyl; [0070] R.sub.10 is selected from hydrogen, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, halogen, hydroxy, OR.sub.6, OC(O)R.sub.6, OC(O)OR.sub.6, or OSO.sub.2R.sub.6; [0071] R.sub.11 is selected from hydrogen, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C(O)R.sub.6, C(O)OR.sub.6, or SO.sub.2R.sub.6; and [0072] X.sup. is a pharmaceutically acceptable anion.

[0073] In formula (I), R.sub.1, R.sub.2, and R.sub.3 are each independently chosen from a C.sub.1-C.sub.6 alkyl, or C.sub.2-C.sub.6 alkenyl. R.sub.1, R.sub.2, and R.sub.3 may each independently be a straight chain or branched C.sub.1-C.sub.6 alkyl, for example a straight chain C.sub.1-C.sub.6 alkyl, or a straight chain or branched C.sub.2-C.sub.6 alkenyl, for example allyl, 2-butenyl, etc. In some embodiments R.sub.1, R.sub.2, and R.sub.3 may each independently be a straight chain or branched C.sub.1-C.sub.4 alkyl, for example a straight chain C.sub.1-C.sub.4 alkyl, or a C.sub.2-C.sub.4 alkenyl. R.sub.1, R.sub.2, and R.sub.3 may each independently be selected from methyl, ethyl, n-propyl, isopropyl, cyclopropyl, n-butyl, isobutyl, or tert-butyl. In other embodiments, R.sub.1, R.sub.2, and R.sub.3 may each independently be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, and tert-butyl. In other embodiments, R.sub.1, R.sub.2, and R.sub.3 are each methyl, are each ethyl, or a mixture of methyl and ethyl groups.

[0074] In formula (I), one of R.sub.4 and R.sub.5 is hydrogen and the other of R.sub.4 and R.sub.5 is OSO.sub.2R.sub.6. R.sub.6 is a C.sub.1-C.sub.6 alkyl or a substituted or unsubstituted aryl. R.sub.6 may be a straight chain or branched C.sub.1-C.sub.4 alkyl, for example a straight chain C.sub.1-C.sub.4 alkyl. In some embodiments, R.sub.6 is selected from methyl, ethyl, n-propyl, or n-butyl, and for example is methyl or ethyl. R.sub.6 may also be a substituted or unsubstituted aryl. An aryl is a 6- to 14-membered aromatic ring, preferably a 6- to 10-membered aromatic ring and includes polycyclic ring systems in which two or more carbon atoms are common to adjoining rings where at least one ring is aromatic. Examples of aryl groups include, but are not limited to phenyl, naphthyl, anthracenyl, and phenantherenyl. An aryl group may be substituted with one or more C.sub.1-C.sub.4 alkyl or perfluoralkyl groups, C.sub.1-C.sub.4 hydroxyalkyl groups, hydroxyl groups, nitro groups or halo groups (e.g. F, Cl, I or Br). An aryl group may be ortho-, meta- and/or para-substituted, preferably para-substituted. When an aryl group is substituted with one or more straight chain or branched C.sub.1-C.sub.4 alkyl perfluoralkyl groups the group may be methyl, trifluoromethyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, or tert-butyl or the group may be methyl, ethyl, isopropyl, or tert-butyl. When R.sub.4 or R.sub.5 is OSO.sub.2R.sub.6, R.sub.6 may be a methyl, a tert-butyl, a phenyl, a benzyl, a para-halophenyl or a para-tolyl group.

[0075] In formula (I), R.sub.7, R.sub.8, and R.sub.9 are each independently hydrogen or C.sub.1-C.sub.6 alkyl, for example a straight chain C.sub.1-C.sub.4 alkyl. In some embodiments, R.sub.7, R.sub.8, and R.sub.9 are each independently selected from hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, and isobutyl. In other embodiments, R.sub.7, R.sub.8, and R.sub.9 are each independently hydrogen, methyl, or ethyl.

[0076] In formula (I), R.sub.10 is selected from hydrogen, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, halogen, hydroxy, OR.sub.6, OC(O)R.sub.6, OC(O)OR.sub.6, or OSO.sub.2R.sub.6. R.sub.10 may be a straight chain or branched C.sub.1-C.sub.6 alkyl, for example a straight chain C.sub.1-C.sub.6 alkyl, or a straight chain or branched C.sub.2-C.sub.6 alkenyl, for example allyl, 2-butenyl, etc. In some embodiments R.sub.10 may be a straight chain or branched C.sub.1-C.sub.4 alkyl, for example a straight chain C.sub.1-C.sub.4 alkyl, or a C.sub.2-C.sub.4 alkenyl. R.sub.10 may be selected from methyl, ethyl, n-propyl, isopropyl, cyclopropyl, n-butyl, isobutyl, or tert-butyl. In other embodiments, R.sub.10 may be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, and tert-butyl. R.sub.10 may be a halogen. Exemplary halogens include fluorine (F), chlorine (Cl), bromine (Br), and iodine (I). In some embodiments, R.sub.10 may be selected from OR.sub.6, OC(O)R.sub.6, OC(O)OR.sub.6, or OSO.sub.2R.sub.6, wherein R.sub.6 is a C.sub.1-C.sub.6 alkyl or a substituted or unsubstituted aryl. R.sub.6 may be a straight chain or branched C.sub.1-C.sub.4 alkyl, for example a straight chain C.sub.1-C.sub.4 alkyl. In some embodiments, R.sub.6 is selected from methyl, ethyl, n-propyl, or n-butyl, and for example is methyl or ethyl. R.sub.6 may also be a substituted or unsubstituted aryl. An aryl is a 6- to 14-membered aromatic ring, preferably a 6- to 10-membered aromatic ring and includes polycyclic ring systems in which two or more carbon atoms are common to adjoining rings where at least one ring is aromatic. Examples of aryl groups include, but are not limited to phenyl, naphthyl, anthracenyl, and phenantherenyl. An aryl group may be substituted with one or more C.sub.1-C.sub.4 alkyl or perfluoralkyl groups, C.sub.1-C.sub.4 hydroxyalkyl groups, hydroxyl groups, nitro groups or halo groups (e.g. F, Cl, I or Br). An aryl group may be ortho-, meta- and/or para-substituted, preferably para-substituted. When an aryl group is substituted with one or more straight chain or branched C.sub.1-C.sub.4 alkyl perfluoralkyl groups the group may be methyl, trifluoromethyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, or tert-butyl or the group may be methyl, ethyl, isopropyl, or tert-butyl. When R.sub.10 is OSO.sub.2R.sub.6, R.sub.6 may be a methyl, a tert-butyl, a phenyl, a benzyl, a para-halophenyl or a para-tolyl group.

[0077] In formula (I), R.sub.11 is selected from hydrogen, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C(O)R.sub.6, C(O)OR.sub.6, or SO.sub.2R.sub.6. R.sub.11 may be a straight chain or branched C.sub.1-C.sub.6 alkyl, for example a straight chain C.sub.1-C.sub.6 alkyl, or a straight chain or branched C.sub.2-C.sub.6 alkenyl, for example allyl, 2-butenyl, etc. In some embodiments, R.sub.11 may be a straight chain or branched C.sub.1-C.sub.4 alkyl, for example a straight chain C.sub.1-C.sub.4 alkyl, or a C.sub.2-C.sub.4 alkenyl. R.sub.11 may be selected from methyl, ethyl, n-propyl, isopropyl, cyclopropyl, n-butyl, isobutyl, or tert-butyl. In other embodiments, R.sub.11 may be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, and tert-butyl. In some embodiments, Ra may be selected from C(O)R.sub.6, C(O)OR.sub.6, or SO.sub.2R.sub.6, wherein R.sub.6 is a C.sub.1-C.sub.6 alkyl or a substituted or unsubstituted aryl. R.sub.6 may be a straight chain or branched C.sub.1-C.sub.4 alkyl, for example a straight chain C.sub.1-C.sub.4 alkyl. In some embodiments, R.sub.6 is selected from methyl, ethyl, n-propyl, or n-butyl, and for example is methyl or ethyl. R.sub.6 may also be a substituted or unsubstituted aryl. An aryl is a 6- to 14-membered aromatic ring, preferably a 6- to 10-membered aromatic ring and includes polycyclic ring systems in which two or more carbon atoms are common to adjoining rings where at least one ring is aromatic. Examples of aryl groups include, but are not limited to phenyl, naphthyl, anthracenyl, and phenantherenyl. An aryl group may be substituted with one or more C.sub.1-C.sub.4 alkyl or perfluoralkyl groups, C.sub.1-C.sub.4 hydroxyalkyl groups, hydroxyl groups, nitro groups or halo groups (e.g. F, Cl, I or Br). An aryl group may be ortho-, meta- and/or para-substituted, preferably para-substituted. When an aryl group is substituted with one or more straight chain or branched C.sub.1-C.sub.4 alkyl perfluoralkyl groups the group may be methyl, trifluoromethyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, or tert-butyl or the group may be methyl, ethyl, isopropyl, or tert-butyl.

[0078] The anion of formula (I), X.sup., may be any pharmaceutically acceptable anion, for example, Cl.sup., I.sup., Br, ascorbate, hydrofumarate, fumarate, maleate, and the like. A preferred anion, X.sup., is iodide, I.sup.. When the pharmaceutically acceptable anion is a di-anion it balances two of the ammonium cations.

[0079] A compound of formula (Ia) (below) is reacted with XR.sub.3, where XR.sub.3 is an alkyl agent, by refluxing in an appropriate organic solvent, such as methanol or THF, under an inert atmosphere, to prepare a compound of formula (I).

##STR00006##

[0080] The reaction is shown in the following reaction:

##STR00007##

[0081] A compound of formula (Ia) is treated with an alkyl agent. For example, the alkyl agent may be an alkyl halide, an alkyl iodide, a methyl iodide, an ethyl iodide, a propyl iodide, or a butyl iodide.

[0082] In a preferred embodiment, XR.sub.3 is ICH.sub.3 or ICH.sub.2CH.sub.3. When R.sub.4 or R.sub.5 of formula (Ia) is hydroxyl it can be converted to OSO.sub.2R.sub.6, as is known in the art. Hydroxyl groups may be introduced by hydrolysis of a corresponding ester. Other pharmaceutically acceptable salts may be prepared by anion exchange techniques known in the art to exchange the iodide anion for a desired pharmaceutically acceptable anion. For example, the iodide anion may be exchanged using an anion exchange resin.

[0083] Exemplary compounds prepared by the above reaction can be found in Tables 1 and 2. Table 1 contains the exemplary reactants and Table 2 contains the corresponding products.

TABLE-US-00001 TABLE 1 Reactants Formula (Ia) (R.sub.7, R.sub.8, R.sub.9, R.sub.10, and R.sub.11 are H) XR.sub.3 Compound R.sub.1 R.sub.2 R.sub.4 R.sub.5 XR.sub.3 1 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2CH.sub.3 H ICH.sub.3 2 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2CH.sub.3 H ICH.sub.2CH.sub.3 3 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2CH.sub.3 H ICH.sub.2CH.sub.2CH.sub.3 4 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2CH.sub.3 H ICH.sub.2CH.sub.2CH.sub.2CH.sub.3 5 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2CH.sub.2CH.sub.3 H ICH.sub.3 6 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2CH.sub.2CH.sub.3 H ICH.sub.2CH.sub.3 7 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2CH.sub.2CH.sub.3 H ICH.sub.2CH.sub.2CH.sub.3 8 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2CH.sub.2CH.sub.3 H ICH.sub.2CH.sub.2CH.sub.2CH.sub.3 9 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2CH.sub.2CH.sub.2CH.sub.3 H ICH.sub.3 10 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2CH.sub.2CH.sub.2CH.sub.3 H ICH.sub.2CH.sub.3 11 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2CH.sub.2CH.sub.2CH.sub.3 H ICH.sub.2CH.sub.2CH.sub.3 12 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2CH.sub.2CH.sub.2CH.sub.3 H ICH.sub.2CH.sub.2CH.sub.2CH.sub.3 13 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.5 H ICH.sub.3 14 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.5 H ICH.sub.2CH.sub.3 15 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.5 H ICH.sub.2CH.sub.2CH.sub.3 16 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.5 H ICH.sub.2CH.sub.2CH.sub.2CH.sub.3 17 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.4CH.sub.3 H ICH.sub.3 18 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.4CH.sub.3 H ICH.sub.2CH.sub.3 19 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.4CH.sub.3 H ICH.sub.2CH.sub.2CH.sub.3 20 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.4CH.sub.3 H ICH.sub.2CH.sub.2CH.sub.2CH.sub.3 21 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.4CF.sub.3 H ICH.sub.3 22 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.4CF.sub.3 H ICH.sub.2CH.sub.3 23 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.4CF.sub.3 H ICH.sub.2CH.sub.2CH.sub.3 24 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.4CF.sub.3 H ICH.sub.2CH.sub.2CH.sub.2CH.sub.3 25 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.4NO.sub.2 H ICH.sub.3 26 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.4NO.sub.2 H ICH.sub.2CH.sub.3 27 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.4NO.sub.2 H ICH.sub.2CH.sub.2CH.sub.3 28 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.4NO.sub.2 H ICH.sub.2CH.sub.2CH.sub.2CH.sub.3 29 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.4Cl H ICH.sub.3 30 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.4Cl H ICH.sub.2CH.sub.3 31 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.4Cl H ICH.sub.2CH.sub.2CH.sub.3 32 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.4Cl H ICH.sub.2CH.sub.2CH.sub.2CH.sub.3 33 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.4Br H ICH.sub.3 34 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.4Br H ICH.sub.2CH.sub.3 35 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.4Br H ICH.sub.2CH.sub.2CH.sub.3 36 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.4Br H ICH.sub.2CH.sub.2CH.sub.2CH.sub.3 37 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.4F H ICH.sub.3 38 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.4F H ICH.sub.2CH.sub.3 39 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.4F H ICH.sub.2CH.sub.2CH.sub.3 40 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.4F H ICH.sub.2CH.sub.2CH.sub.2CH.sub.3

TABLE-US-00002 TABLE 2 Products Formula (I) (R.sub.7, R.sub.8, R.sub.9, R.sub.10, and R.sub.11 are H) Compound R.sub.1 R.sub.2 R.sub.3 R.sub.4 R.sub.5 X.sup. 1 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 CH.sub.3 OSO.sub.2CH.sub.3 H I.sup. 2 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.3 OSO.sub.2CH.sub.3 H I.sup. 3 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2CH.sub.3 H I.sup. 4 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2CH.sub.3 H I.sup. 5 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 CH.sub.3 OSO.sub.2CH.sub.2CH.sub.3 H I.sup. 6 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.3 OSO.sub.2CH.sub.2CH.sub.3 H I.sup. 7 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2CH.sub.2CH.sub.3 H I.sup. 8 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2CH.sub.2CH.sub.3 H I.sup. 9 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 CH.sub.3 OSO.sub.2CH.sub.2CH.sub.2CH.sub.3 H I.sup. 10 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.3 OSO.sub.2CH.sub.2CH.sub.2CH.sub.3 H I.sup. 11 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2CH.sub.2CH.sub.2CH.sub.3 H I.sup. 12 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2CH.sub.2CH.sub.2CH.sub.3 H I.sup. 13 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 CH.sub.3 OSO.sub.2C.sub.6H.sub.5 H I.sup. 14 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.5 H I.sup. 15 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.5 H I.sup. 16 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.5 H I.sup. 17 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 CH.sub.3 OSO.sub.2C.sub.6H.sub.4CH.sub.3 H I.sup. 18 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.4CH.sub.3 H I.sup. 19 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.4CH.sub.3 H I.sup. 20 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.4CH.sub.3 H I.sup. 21 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 CH.sub.3 OSO.sub.2C.sub.6H.sub.4CF.sub.3 H I.sup. 22 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.4CF.sub.3 H I.sup. 23 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.4CF.sub.3 H I.sup. 24 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.4CF.sub.3 H I.sup. 25 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 CH.sub.3 OSO.sub.2C.sub.6H.sub.4NO.sub.2 H I.sup. 26 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.4NO.sub.2 H I.sup. 27 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.4NO.sub.2 H I.sup. 28 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.4NO.sub.2 H I.sup. 29 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 CH.sub.3 OSO.sub.2C.sub.6H.sub.4Cl H I.sup. 30 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.4Cl H I.sup. 31 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.4Cl H I.sup. 32 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.4Cl H I.sup. 33 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 CH.sub.3 OSO.sub.2C.sub.6H.sub.4Br H I.sup. 34 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.4Br H I.sup. 35 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.4Br H I.sup. 36 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.4Br H I.sup. 37 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 CH.sub.3 OSO.sub.2C.sub.6H.sub.4F H I.sup. 38 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.4F H I.sup. 39 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.4F H I.sup. 40 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.2CH.sub.3 OSO.sub.2C.sub.6H.sub.4F H I.sup.

[0084] This disclosure also relates to a compound of formula (II):

##STR00008##

[0085] wherein: [0086] R.sub.1, R.sub.2, and R.sub.3 are each independently a straight chain or branched C.sub.1-C.sub.6 alkyl or C.sub.2-C.sub.6 alkenyl; [0087] R.sub.4 is hydrogen, hydroxy, OR.sub.5, OC(O)R.sub.5, OC(O)OR.sub.5, or OSO.sub.2R.sub.5; [0088] R.sub.5 is a straight chain or branched C.sub.1-C.sub.6 alkyl or a substituted or unsubstituted aryl; [0089] R.sub.6 is a halogen chosen from F, Cl, Br, and I; and [0090] R.sub.7, R.sub.8, R.sub.9, and R.sub.10 are each independently hydrogen or a straight chain or branched C.sub.1-C.sub.6 alkyl; [0091] R.sub.11 is selected from hydrogen, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C(O)R.sub.5, C(O)OR.sub.5, or SO.sub.2R.sub.5; and [0092] X.sup. is a pharmaceutically acceptable anion.

[0093] In formula (II), R.sub.1, R.sub.2, and R.sub.3 are each independently a straight chain or branched C.sub.1-C.sub.6 alkyl or C.sub.2-C.sub.6 alkenyl, such as a straight-chained C.sub.1-C.sub.6 alkyl (e.g., methyl, ethyl, n-propyl). In some embodiments, R.sub.1, R.sub.2, and R.sub.3 are each independently a straight chain or branched C.sub.2-C.sub.6 alkyl or C.sub.3-C.sub.6 alkyl. In some embodiments, R.sub.1, R.sub.2, and R.sub.3 are each independently selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, and isobutyl.

[0094] In formula (II), R.sub.4 is hydrogen, hydroxy, OR.sub.5, OC(O)R.sub.5, OC(O)OR.sub.5, or OSO.sub.2R.sub.5. When R.sub.4 is C.sub.1-C.sub.6 alkoxy group, or in some embodiments a C.sub.1-C.sub.4 alkoxy group, it may be a straight chain or branched C.sub.1-C.sub.6 alkoxy group or C.sub.1-C.sub.4 alkoxy group, for example a straight chain, and may be methoxy or ethoxy. R.sub.5 is a straight chain or branched C.sub.1-C.sub.6 alkyl or a substituted or unsubstituted aryl. When R.sub.5 is a straight chain or branched C.sub.1-C.sub.6 alkyl, it may be a straight chain or branched C.sub.1-C.sub.4 alkyl, for example a straight chain C.sub.1-C.sub.4 alkyl. In some embodiments, R.sub.5 is selected from methyl, ethyl, n-propyl or n-butyl, and for example is methyl or ethyl. R.sub.5 may also be a substituted or unsubstituted aryl. An aryl is a 6- to 14-membered aromatic ring, preferably a 6- to 10-membered aromatic ring and includes polycyclic ring systems in which two or more carbon atoms are common to adjoining rings where at least one ring is aromatic. Examples of aryl groups include, but are not limited to phenyl, naphthyl, anthracenyl and phenantherenyl. An aryl group may be substituted with one or more straight chain or branched C.sub.1-C.sub.4 alkyl groups, straight chain or branched C.sub.1-C.sub.4 hydroxyalkyl groups, hydroxyl groups or halo groups (e.g. F, Cl, I or Br). When an aryl group is substituted with one or more straight chain or branched C.sub.1-C.sub.4 alkyl groups the group may be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl or the group may be methyl, ethyl, isopropyl, or tert-butyl. When R.sub.4 is OR.sub.5, OC(O)R.sub.5, OC(O)OR.sub.5, or OSO.sub.2R.sub.5, R.sub.5 may be a methyl, a tert-butyl, a phenyl or a para-tolyl group.

[0095] In formula (II), R.sub.6 is a halogen. Exemplary halogens include fluorine (F), chlorine (Cl), bromine (Br), and iodine (I).

[0096] R.sub.7, R.sub.8, R.sub.9, and R.sub.10 in formula (II) are each independently hydrogen or a straight chain or branched C.sub.1-C.sub.4 alkyl, for example a straight chain C.sub.1-C.sub.4 alkyl. In some embodiments, R.sub.7, R.sub.8, R.sub.9, and R.sub.10 are each independently selected from C.sub.2-C.sub.6 alkyl or C.sub.3-C.sub.6 alkyl. In some embodiments, R.sub.7, R.sub.8, R.sub.9, and R.sub.10 are each independently selected from hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, and isobutyl. In other embodiments, R.sub.7, R.sub.8, R.sub.9, and R.sub.10 are each independently hydrogen, methyl, or ethyl.

[0097] In formula (II), R.sub.11 is selected from hydrogen, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C(O)R.sub.5, C(O)OR.sub.5, or SO.sub.2R.sub.5. R.sub.11 may be a straight chain or branched C.sub.1-C.sub.6 alkyl, for example a straight chain C.sub.1-C.sub.6 alkyl, or a straight chain or branched C.sub.2-C.sub.6 alkenyl, for example allyl, 2-butenyl, etc. In some embodiments, R.sub.11 may be a straight chain or branched C.sub.1-C.sub.4 alkyl, for example a straight chain C.sub.1-C.sub.4 alkyl, or a C.sub.2-C.sub.4 alkenyl. R.sub.11 may be selected from methyl, ethyl, n-propyl, isopropyl, cyclopropyl, n-butyl, isobutyl, or tert-butyl. In other embodiments, R.sub.11 may be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, and tert-butyl. In some embodiments, R.sub.11 may be selected from C(O)R.sub.5, C(O)OR.sub.5, or SO.sub.2R.sub.5, wherein R.sub.5 is a straight chain or branched C.sub.1-C.sub.6 alkyl or a substituted or unsubstituted aryl. When R.sub.5 is a straight chain or branched C.sub.1-C.sub.6 alkyl, it may be a straight chain or branched C.sub.1-C.sub.4 alkyl, for example a straight chain C.sub.1-C.sub.4 alkyl. In some embodiments, R.sub.5 is selected from methyl, ethyl, n-propyl or n-butyl, and for example is methyl or ethyl. R.sub.5 may also be a substituted or unsubstituted aryl. An aryl is a 6- to 14-membered aromatic ring, preferably a 6- to 10-membered aromatic ring and includes polycyclic ring systems in which two or more carbon atoms are common to adjoining rings where at least one ring is aromatic. Examples of aryl groups include, but are not limited to phenyl, naphthyl, anthracenyl and phenantherenyl. An aryl group may be substituted with one or more straight chain or branched C.sub.1-C.sub.4 alkyl groups, straight chain or branched C.sub.1-C.sub.4 hydroxyalkyl groups, hydroxyl groups or halo groups (e.g. F, Cl, I or Br). When an aryl group is substituted with one or more straight chain or branched C.sub.1-C.sub.4 alkyl groups the group may be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl or the group may be methyl, ethyl, isopropyl, or tert-butyl.

[0098] In one embodiment, formula (II) contains the proviso that when R.sub.1, R.sub.2, and R.sub.3 are methyl and R.sub.4, R.sub.7, R.sub.8, R.sub.9, R.sub.10, and R.sub.11 are hydrogen, R.sub.6 is not Br.

[0099] In one embodiment of the compound of formula (II), R.sub.1, R.sub.2, and R.sub.3 are each independently a straight chain or branched C.sub.1-C.sub.6 alkyl.

[0100] In one embodiment of the compound of formula (II), R.sub.1 is a straight chain or branched C.sub.1-C.sub.6 alkyl.

[0101] In one embodiment of the compound of formula (II), R.sub.1 is a straight chain or branched C.sub.2-C.sub.6 alkyl.

[0102] In one embodiment of the compound of formula (II), R.sub.1 is a straight chain or branched C.sub.3-C.sub.6 alkyl.

[0103] In one embodiment of the compound of formula (II), R.sub.2 is a straight chain or branched C.sub.1-C.sub.6 alkyl.

[0104] In one embodiment of the compound of formula (II), R.sub.2 is a straight chain or branched C.sub.2-C.sub.6 alkyl.

[0105] In one embodiment of the compound of formula (II), R.sub.2 is a straight chain or branched C.sub.3-C.sub.6 alkyl.

[0106] In one embodiment of the compound of formula (II), R.sub.3 is a straight chain or branched C.sub.1-C.sub.6 alkyl.

[0107] In one embodiment of the compound of formula (II), R.sub.3 is a straight chain or branched C.sub.2-C.sub.6 alkyl.

[0108] In one embodiment of the compound of formula (II), R.sub.3 is a straight chain or branched C.sub.3-C.sub.6 alkyl.

[0109] In one embodiment of the compound of formula (II), one or more of R.sub.1, R.sub.2, and R.sub.3 is C.sub.2-C.sub.6 alkenyl.

[0110] In one embodiment of the compound of formula (II), R.sub.4 is hydrogen.

[0111] In one embodiment of the compound of formula (II), R.sub.4 is hydroxy.

[0112] In one embodiment of the compound of formula (II), R.sub.4 is OR.sub.5.

[0113] In one embodiment of the compound of formula (II), R.sub.4 is OC(O)R.sub.5.

[0114] In one embodiment of the compound of formula (II), R.sub.4 is OC(O)OR.sub.5.

[0115] In one embodiment of the compound of formula (II), R.sub.4 is OSO.sub.2R.sub.5.

[0116] In one embodiment of the compound of formula (II), R.sub.6 is chloro.

[0117] In one embodiment of the compound of formula (II), R.sub.6 is bromo.

[0118] In one embodiment of the compound of formula (II), R.sub.6 is iodo.

[0119] In one embodiment of the compound of formula (II), R.sub.6 is fluoro.

[0120] In one embodiment of the compound of formula (II), R.sub.7 is hydrogen.

[0121] In one embodiment of the compound of formula (II), R.sub.7 is a straight chain or branched C.sub.1-C.sub.6 alkyl.

[0122] In one embodiment of the compound of formula (II), R.sub.7 is a straight chain or branched C.sub.2-C.sub.6 alkyl.

[0123] In one embodiment of the compound of formula (II), R.sub.7 is a straight chain or branched C.sub.3-C.sub.6 alkyl.

[0124] In one embodiment of the compound of formula (II), R.sub.8 is hydrogen.

[0125] In one embodiment of the compound of formula (II), R.sub.8 is a straight chain or branched C.sub.1-C.sub.6 alkyl.

[0126] In one embodiment of the compound of formula (II), R.sub.8 is a straight chain or branched C.sub.2-C.sub.6 alkyl.

[0127] In one embodiment of the compound of formula (II), R.sub.8 is a straight chain or branched C.sub.3-C.sub.6 alkyl.

[0128] In one embodiment of the compound of formula (II), R.sub.9 is hydrogen.

[0129] In one embodiment of the compound of formula (II), R.sub.9 is a straight chain or branched C.sub.1-C.sub.6 alkyl.

[0130] In one embodiment of the compound of formula (II), R.sub.9 is a straight chain or branched C.sub.2-C.sub.6 alkyl.

[0131] In one embodiment of the compound of formula (II), R.sub.9 is a straight chain or branched C.sub.3-C.sub.6 alkyl.

[0132] In one embodiment of the compound of formula (II), two of R.sub.1, R.sub.2, and R.sub.3 are the same.

[0133] In one embodiment of the compound of formula (II), R.sub.1, R.sub.2, and R.sub.3 are the same.

[0134] In one embodiment of the compound of formula (II), X.sup. is iodo.

[0135] In one embodiment of the compound of formula (II), each of R.sub.1, R.sub.2, and R.sub.3 is independently selected from straight chain or branched C.sub.3-C.sub.6 alkyl; R.sub.4 is hydrogen; R.sub.6 is selected from chloro, iodo, bromo, and fluoro; and each of R.sub.7, R.sub.8, and R.sub.9 is hydrogen. In one embodiment, each of R.sub.1, R.sub.2, and R.sub.3 is propyl. In one embodiment of the compound of formula (II), X.sup. is iodo.

[0136] In one embodiment of the compound of formula (II), each of R.sub.1, R.sub.2, and R.sub.3 is independently selected from straight chain or branched C.sub.2-C.sub.6 alkyl; R.sub.4 is hydrogen; R.sub.6 is selected from chloro, iodo, bromo, and fluoro; and each of R.sub.7, R.sub.8, and R.sub.9 is hydrogen. In one embodiment, each of R.sub.1, R.sub.2, and R.sub.3 is ethyl. In one embodiment of the compound of formula (II), X.sup. is iodo.

[0137] In one embodiment of the compound of formula (II), each of R.sub.1, R.sub.2, and R.sub.3 is methyl; R.sub.4 is hydrogen; R.sub.6 is selected from chloro, iodo, and fluoro; and each of R.sub.7, R.sub.8, and R.sub.9 is hydrogen. In one embodiment of the compound of formula (II), X.sup. is iodo.

[0138] Pharmaceutically acceptable salts for a compound of formula (II) may be any acid (e.g. HX or H.sub.2X) addition salts. The anion, X.sup., may be any pharmaceutically acceptable anion, for example, Cl.sup., I.sup., B.sup., ascorbate, hydrofumarate, fumarate, maleate, and the like. When the pharmaceutically acceptable anion is a di-anion it balances two of the ammonium cations. Other pharmaceutically acceptable salts may be prepared by anion exchange techniques known in the art to exchange the iodide anion for a desired pharmaceutically acceptable anion. For example, the iodide anion may be exchanged using an anion exchange resin.

[0139] A compound of formula (II) may be prepared by a variety of methods known in the organic synthesis art. In some cases, compounds of formula (II) may be prepared by treating a 5-halo tryptamine with excess alkyl halide.

[0140] A compound of formula (IIa) (below) is reacted with XR.sub.3, where XR.sub.3 is an alkyl halide, by refluxing in an appropriate organic solvent, such as isopropanol, under an inert atmosphere, to prepare a compound of formula (II).

##STR00009##

[0141] The reaction is shown in the following reaction:

##STR00010##

[0142] A compound of formula (IIa) is treated with an alkyl halide. For example, the alkyl halide may be an alkyl iodide, a methyl iodide, an ethyl iodide, a propyl iodide, or a butyl iodide.

[0143] In a preferred embodiment, XR.sub.3 is ICH.sub.3, ICH.sub.2CH.sub.3, or ICH.sub.2CH.sub.2CH.sub.3. Other pharmaceutically acceptable salts may be prepared by anion exchange techniques known in the art to exchange the iodide anion for a desired pharmaceutically acceptable anion. For example, the iodide anion may be exchanged using an anion exchange resin.

[0144] Exemplary compounds prepared by the above reaction can be found in Tables 3 and 4. Table 3 contains the exemplary reactants and Table 4 contains the corresponding products.

TABLE-US-00003 TABLE 3 Reactants Formula (IIa) (R.sub.4, R.sub.7, R.sub.8, R.sub.9, R.sub.10, and R.sub.11 are H) XR.sub.3 Compound R.sub.1 R.sub.2 R.sub.6 XR.sub.3 1 CH.sub.3 CH.sub.3 F ICH.sub.3 2 CH.sub.2CH.sub.3 CH.sub.2CH.sub.3 F ICH.sub.2CH.sub.3 3 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 F ICH.sub.2CH.sub.2CH.sub.3 4 CH.sub.2CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.2CH.sub.3 F ICH.sub.2CH.sub.2CH.sub.2CH.sub.3 5 CH.sub.3 CH.sub.3 Cl ICH.sub.3 6 CH.sub.2CH.sub.3 CH.sub.2CH.sub.3 Cl ICH.sub.2CH.sub.3 7 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 Cl ICH.sub.2CH.sub.2CH.sub.3 8 CH.sub.2CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.2CH.sub.3 Cl ICH.sub.2CH.sub.2CH.sub.2CH.sub.3 9 CH.sub.3 CH.sub.3 Br ICH.sub.3 10 CH.sub.2CH.sub.3 CH.sub.2CH.sub.3 Br ICH.sub.2CH.sub.3 11 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 Br ICH.sub.2CH.sub.2CH.sub.3 12 CH.sub.2CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.2CH.sub.3 Br ICH.sub.2CH.sub.2CH.sub.2CH.sub.3 13 CH.sub.3 CH.sub.3 I ICH.sub.3 14 CH.sub.2CH.sub.3 CH.sub.2CH.sub.3 I ICH.sub.2CH.sub.3 15 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 I ICH.sub.2CH.sub.2CH.sub.3 16 CH.sub.2CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.2CH.sub.3 I ICH.sub.2CH.sub.2CH.sub.2CH.sub.3

TABLE-US-00004 TABLE 4 Products Formula (II) (R.sub.4, R.sub.7, R.sub.8, R.sub.9, R.sub.10, and R.sub.11 are H) Compound R.sub.1 R.sub.2 R.sub.3 R.sub.6 X.sup. 1 CH.sub.3 CH.sub.3 CH.sub.3 F I.sup. 2 CH.sub.2CH.sub.3 CH.sub.2CH.sub.3 CH.sub.2CH.sub.3 F I.sup. 3 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 F I.sup. 4 CH.sub.2CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.2CH.sub.3 F I.sup. 5 CH.sub.3 CH.sub.3 CH.sub.3 Cl I.sup. 6 CH.sub.2CH.sub.3 CH.sub.2CH.sub.3 CH.sub.2CH.sub.3 Cl I.sup. 7 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 Cl I.sup. 8 CH.sub.2CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.2CH.sub.3 Cl I.sup. 9 CH.sub.3 CH.sub.3 CH.sub.3 Br I.sup. 10 CH.sub.2CH.sub.3 CH.sub.2CH.sub.3 CH.sub.2CH.sub.3 Br I.sup. 11 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 Br I.sup. 12 CH.sub.2CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.2CH.sub.3 Br I.sup. 13 CH.sub.3 CH.sub.3 CH.sub.3 I I.sup. 14 CH.sub.2CH.sub.3 CH.sub.2CH.sub.3 CH.sub.2CH.sub.3 I I.sup. 15 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.3 I I.sup. 16 CH.sub.2CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.2CH.sub.3 CH.sub.2CH.sub.2CH.sub.2CH.sub.3 I I.sup.

[0145] This disclosure relates to specific compounds of formula (II) as shown in Table 5 and the crystalline forms of those compounds disclosed herein.

TABLE-US-00005 TABLE 5 [00011] embedded image Compound Structural Formula 5-fluoro-N,N,N-trimethyltryptammonium (5-F-TMT) iodide [00012] 5-fluoro-N,N,N-triethyltryptammonium (5- F-TET) iodide [00013] 5-fluoro-N,N,N-tri-n- propyltryptammonium (5-F-TPT) iodide [00014] 5-chloro-N,N,N-trimethyltrptammonium (5-Cl-TMT) iodide [00015] 5-chloro-N,N,N-triethyltryptammonium (5- Cl-TET) iodide [00016] embedded image 5-bromo-N,N,N-triethyltryptammonium (5-Br-TET) iodide [00017] 5-bromo-N,N,N-tri-n- propyltryptammonium (5-Br-TPT) iodide [00018] 5-bromo-N,N,N-tri-n- propyltryptammonium (5-Br-TPT) iodide acetonitrile solvate [00019]

[0146] Methods of Treatment and Therapeutic Uses

[0147] In one embodiment, the compounds of formula (I) or formula (II), according to the disclosure, crystalline forms thereof, and the methods and the compositions (e.g., pharmaceutical compositions) of the disclosure are used to regulate the activity of a neurotransmitter receptor by administering a therapeutically effective dose of compounds of formula (I) or formula (II) according to the disclosure. In another embodiment, the compounds of formula (I) or formula (II), according to the disclosure, and the methods and the compositions (e.g., pharmaceutical compositions) of the disclosure are used to treat inflammation and/or pain by administering a therapeutically effective dose of compounds of formula (I) or formula (II) according to the disclosure.

[0148] Methods of the disclosure administer a therapeutically effective amount of compounds of formula (I) or formula (II) to prevent or treat a disease or condition, such as those discussed below. Compounds of formula (I) or formula (II) may be administered neat or as a pharmaceutical composition comprising compounds of formula (I) or formula (II) as discussed below.

[0149] Compounds of formula (I) or formula (II), as described herein, may be used to prevent and/or treat a psychological disorder. The disclosure provides a method for preventing and/or treating a psychological disorder by administering to a subject in need thereof a therapeutically effective amount of compounds of formula (I) or formula (II), including the exemplary embodiments discussed herein. The psychological disorder may be chosen from depression, psychotic disorder, schizophrenia, schizophreniform disorder (acute schizophrenic episode); schizoaffective disorder; bipolar I disorder (mania, manic disorder, manic-depressive psychosis); bipolar II disorder; major depressive disorder; major depressive disorder with psychotic feature (psychotic depression); delusional disorders (paranoia); Shared Psychotic Disorder (Shared paranoia disorder); Brief Psychotic disorder (Other and Unspecified Reactive Psychosis); Psychotic disorder not otherwise specified (Unspecified Psychosis); paranoid personality disorder; schizoid personality disorder; schizotypal personality disorder; anxiety disorder; social anxiety disorder; substance-induced anxiety disorder; selective mutism; panic disorder; panic attacks; agoraphobia; attention deficit syndrome, post-traumatic stress disorder (PTSD), premenstrual dysphoric disorder (PMDD), and premenstrual syndrome (PMS).

[0150] Compounds of formula (I) or formula (II) according to the disclosure may be used to prevent and/or treat a brain disorder. The disclosure provides a method for preventing and/or treating a brain disorder by administering to a subject in need thereof a therapeutically effective amount of compounds of formula (I) or formula (II) including, but not limited to, the exemplary embodiments discussed herein. The brain disorder may be chosen from Huntington's disease, Alzheimer's disease, dementia, and Parkinson's disease.

[0151] Compounds of formula (I) or formula (II) according to the disclosure may be used to prevent and/or treat developmental disorders, delirium, dementia, amnestic disorders and other cognitive disorders, psychiatric disorders due to a somatic condition, drug-related disorders, schizophrenia and other psychotic disorders, mood disorders, anxiety disorders, somatoform disorders, factitious disorders, dissociative disorders, eating disorders, sleep disorders, impulse control disorders, adjustment disorders, or personality disorders. The disclosure provides a method for preventing and/or treating these disorders by administering to a subject in need thereof a therapeutically effective amount of compounds of formula (I) or formula (II), including, but not limited to, the exemplary embodiments discussed herein.

[0152] Compounds of formula (I) or formula (II) according to the disclosure may be used to prevent and/or treat inflammation and/or pain, such as, for example, inflammation and/or pain associated with inflammatory skeletal or muscular diseases or conditions. Accordingly, the disclosure relates to a method for preventing and/or treating inflammation and/or pain by administering to a subject in need thereof a therapeutically effective amount of compounds of formula (I) or formula (II), including, but not limited to, the exemplary embodiments discussed herein. Generally speaking, treatable pain includes nociceptive, neuropathic, and mix-type. A method of the disclosure may reduce or alleviate the symptoms associated with inflammation, including, but not limited to, treating localized manifestation of inflammation characterized by acute or chronic swelling, pain, redness, increased temperature, or loss of function in some cases. A method of the disclosure may reduce or alleviate the symptoms of pain regardless of the cause of the pain, including, but not limited to, reducing pain of varying severity, e.g., mild, moderate and severe pain, acute pain and chronic pain. A method of the disclosure is effective in treating joint pain, muscle pain, tendon pain, burn pain, and pain caused by inflammation such as rheumatoid arthritis. Skeletal or muscular diseases or conditions which may be treated include, but are not limited to, musculoskeletal sprains, musculoskeletal strains, tendinopathy, peripheral radiculopathy, osteoarthritis, joint degenerative disease, polymyalgia rheumatica, juvenile arthritis, gout, ankylosing spondylitis, psoriatic arthritis, systemic lupus erythematosus, costochondritis, tendonitis, bursitis, such as the common lateral epicondylitis (tennis elbow), medial epicondylitis (pitchers elbow) and trochanteric bursitis, temporomandibular joint syndrome, and fibromyalgia.

[0153] Compounds of formula (I) or formula (II) according to the disclosure may be used to modulate activity of a mitogen activating protein (MAP), comprising administering a composition of the disclosure. In one embodiment, the mitogen activating protein (MAP) comprises a MAP kinase (MAPk). MAPKs provide a wide-ranging signaling cascade that allow cells to quickly respond to biotic and abiotic stimuli. Exemplary MAPKs include, but are not limited to, Tropomyosin Receptor Kinase A (TrkA), P38-alpha, Janus Kinase 1 (JAK1), and c-Jun N-Terminal Kinase 3 (JNK3). TrkA is a high affinity catalytic receptor of nerve growth factor (NGF) protein. TrkA regulates NGF response, influencing neuronal differentiation and outgrowth as well as programmed cell death. p38-alpha is involved with the regulation of pro-inflammatory cytokines, including TNF-. In the central nervous system, p38-alpha regulates neuronal death and neurite degeneration, and it is a common target of Alzheimer's disease therapies. JAK1 influences cytokine signaling, including IL-2, IL-4, IFN-alpha/beta, IFN-, and IL-10, and it is implicated in brain aging. JNK3 is neuronal specific protein isoform of the JNKs. It is involved with the regulation of apoptosis. JNK3 also plays a role in modulating the response of cytokines, growth factors, and oxidative stress.

[0154] As used herein, the term modulating activity of a mitogen activating protein refers to changing, manipulating, and/or adjusting the activity of a mitogen activating protein. In one embodiment, modulating the activity of a MAP, such as a MAPK, can influence neural health, neurogenesis, neural growth and differentiation, and neurodegenerative diseases.

[0155] Compounds of formula (I) or formula (II) according to the disclosure may be used to modulate neurogenesis, comprising administering a composition of the disclosure. As used herein, the term modulating neurite outgrowth refers to changing, manipulating, and/or adjusting the growth and development of neural projections, or neurites. In one embodiment, neurogenesis comprises modulating the growth of new neurites, the number of neurites per neuron, and/or neurite length. In one embodiment, modulating neurite outgrowth comprises increasing and/or enhancing the rate and/or length at which neurites develop.

[0156] Compounds of formula (I) or formula (II) according to the disclosure may be used to modulate neurite outgrowth, comprising administering a composition of the disclosure. As used herein, the term modulating neurogenesis refers to changing, manipulating, and/or adjusting the growth and development of neural tissue. In one embodiment, neurogenesis comprises adult neurogenesis, in which new neural stem cells are generated from neural stem cells in an adult animal. In one embodiment, modulating neurogenesis comprises increasing and/or enhancing the rate at which new neural tissue is developed.

[0157] The disclosure also relates to methods of preventing or treating sexual health disorders including, but not limited to, hypoactive sexual desire disorder, hyperactive sexual desire disorder, orgasmic disorder, arousal disorder, vaginismus, and dyspareunia. In some embodiments, the disorder is a male sexual dysfunction disorder. In some embodiments. the disorder is a female sexual dysfunction disorder.

[0158] The disclosure also relates to methods of preventing or treating women's health disorders including, but not limited to, menstrual cramping, dysmenorrhea, post-hysterectomic pain, vaginal or vulvar vestibule mucosa disorder, vaginal atrophy, or vulvar vestibulitis.

[0159] The disclosure also relates to a method of generating a dialkyltryptamine compound in situ in a patient, the method comprising administering at least one quaternary tryptamine compound selected from formula (I) or (II) to the patient. The disclosure also relates to methods of generating a dialkyltryptamine compound comprising contacting at least one quaternary tryptamine compound selected from formula (I) or (II) with an enzyme in vitro or in vivo, such as an enzyme capable of nitrogen dealkylation (e.g., cytochrome P450 enzymes (CYPs)). The disclosure further relates to methods of generating a dialkyltryptamine compound in situ in a patient comprising contacting at least one quaternary tryptamine compound selected from formula (I) or (II) with an enzyme in the patient capable of nitrogen dealkylation (e.g., cytochrome P450 enzymes (CYPs)).

[0160] Compositions

[0161] The disclosure also relates to compositions comprising an effective amount of a compound of formula (I) or formula (II), including 5-F-TMT iodide, 5-F-TET iodide, 5-F-TPT iodide, 5-Cl-TMT iodide, 5-Cl-TET iodide, 5-Br-TET iodide, 5-Br-TPT iodide, 5-Br-TPT iodide acetonitrile solvate, their crystalline forms, and crystalline 5-Br-TMT iodide, according to the disclosure (quaternary tryptamine compounds of the disclosure), including its exemplary embodiments discussed above, and an excipient (e.g., a pharmaceutically-acceptable excipient). In another embodiment, the disclosure also relates to pharmaceutical compositions comprising a therapeutically effective amount of a quaternary tryptamine compounds of the disclosure, including its exemplary embodiments discussed above, and a pharmaceutically acceptable excipient (also known as a pharmaceutically acceptable carrier). As discussed above, a quaternary tryptamine compound according to the disclosure may be, for example, therapeutically useful to prevent and/or treat the psychological disorders, brain disorders, pain, and inflammation as well as the other disorders described herein.

[0162] A composition or a pharmaceutical composition of the disclosure may be in any form which contains a quaternary tryptamine compound of the disclosure. The composition may be, for example, a tablet, capsule, liquid suspension, injectable, topical, or transdermal. The compositions generally contain, for example, about 1% to about 99% by weight of a quaternary tryptamine compound of the disclosure and, for example, 99% to 1% by weight of at least one suitable pharmaceutically acceptable excipient. In one embodiment, the composition may be between about 5% and about 75% by weight of a quaternary tryptamine compound of the disclosure, with the rest being at least one suitable pharmaceutically acceptable excipient or at least one other adjuvant, as discussed below.

[0163] Published US applications US 2018/0221396 A1 and US 2019/0142851 A1 disclose compositions comprising a combination of a first purified psilocybin derivative with a second purified psilocybin derivative, with one or two purified cannabinoids or with a purified terpene. Various ratios of these components in the composition are also disclosed. The disclosures of US 2018/0221396 A1 and US 2019/0142851 A1 are incorporated herein by reference. According to this disclosure, a quaternary tryptamine compound of the disclosure may be used as the first purified psilocybin derivative in the compositions described in US 2018/0221396 A1 and US 2019/0142851 A1. Accordingly, this disclosure provides a composition comprising: a first component comprising at least one quaternary tryptamine compound of the disclosure; at least one second component selected from (a) a serotonergic drug, (b) a purified psilocybin derivative, (c) a purified cannabinoid and (d) a purified terpene; and at least one pharmaceutically-acceptable excipient or at least one other adjuvant. Such a composition may be a pharmaceutical composition wherein the components are present individually in therapeutically effective amounts or by combination in a therapeutically effective amount to treat a disease, disorder, or condition as described herein. When used in such compositions as a first component comprising one or more of the quaternary tryptamine compounds of the disclosure with a second component selected from (a) a serotonergic drug, (b) a purified psilocybin derivative, (c) one or two purified cannabinoids, and (d) a purified terpene, the compositions represent particular embodiments of the disclosure. Compositions having a combination of a quaternary tryptamine compound of the disclosure as a first component with a second component selected from (e) an adrenergic drug, (f) a dopaminergic drug, (g) a monoamine oxidase inhibitor, (h) a purified erinacine, and (i) a purified hericenone represent additional particular embodiments of the disclosure represented by the compositions having the quaternary tryptamine compounds of the disclosure. In some embodiments, the first and second components can be administered at the same time (e.g., together in the same composition), or at separate times over the course of treating a patient in need thereof. Such a composition may be a pharmaceutical composition wherein the components are present individually in therapeutically effective amounts or by combination in a therapeutically effective amount to treat a disease, disorder, or condition as described herein.

[0164] A serotonergic drug refers to a compound that binds to, blocks, or otherwise influences (e.g., via an allosteric reaction) activity at a serotonin receptor as described in paragraphs [0245]-[0253] of US 2018/0221396 A1 and [0305]-[0311] US 2019/0142851 A1 as well as the disclosed exemplary embodiments, incorporated here by reference. Exemplary psilocybin derivatives include but are not limited to psilocybin itself and the psilocybin derivates described in paragraphs [0081]-[0109] of US 2018/0221396 A1 and [082]-[0110] US 2019/0142851 A1 as well as the disclosed exemplary embodiments. Exemplary cannabinoids include but are not limited to the cannabinoids described in paragraphs [0111]-[0159] of US 2018/0221396 A1 and [0112]-[0160] US 2019/0142851 A1 as well as the disclosed exemplary embodiments. Exemplary terpenes include but are not limited to the terpenes described in paragraphs [0160]-[0238] of US 2018/0221396 A1 and [0161]-[0300] US 2019/0142851 A1 as well as the disclosed exemplary embodiments.

[0165] A pharmaceutical formulation of the disclosure may comprise, consist essentially of, or consist of (a) at least one quaternary tryptamine compound of the disclosure and (b) at least one second active compound selected from a serotonergic drug, a purified psilocybin derivative, a purified cannabinoid, a purified terpene, an adrenergic drug, a dopaminergic drug, a monoamine oxidase inhibitor, a purified erinacine, or a purified hericenone and (c) a pharmaceutically acceptable excipient. In some embodiments, the quaternary tryptamine compound(s) of the disclosure and the second active compound(s) are each present in a therapeutically effective amount using a purposefully engineered and unnaturally occurring molar ratios. Exemplary molar ratios of the quaternary tryptamine compound of the disclosure to the second active compound in a composition of the disclosure include but are not limited to from about 0.1:100 to about 100:0.1, from about 1:100 to about 100:1, from about 1:50 to about 50:1, from about 1:25 to about 25:1, from about 1:20 to about 20:1, from about 1:10 to about 10:1, from about 1:5 to about 5:1, from about 1:2 to about 2:1 or may be about 1:1.

[0166] A pharmaceutical formulation of the disclosure may comprise a composition containing a quaternary tryptamine compound of the disclosure and a serotonergic drug, a purified psilocybin derivative, a purified cannabinoid, or a purified terpene, each present in a therapeutically effective amount using a purposefully engineered and unnaturally occurring molar ratios. Published US applications US 2018/0221396 A1 and US 2019/0142851 A1 disclose compositions comprising a combination of a purified psilocybin derivative with a second purified psilocybin derivative, with one or two purified cannabinoids or with a purified terpene. The disclosures of US 2018/0221396 A1 and US 2019/0142851 A1 are incorporated herein by reference. According to this disclosure composition containing a quaternary tryptamine compound of the disclosure as discussed above may be used in place of a purified psilocybin derivative in the compositions described in US 2018/0221396 A1 and US 2019/0142851 A1. Accordingly, the disclosure provides a pharmaceutical formulation comprising as (a) at least one quaternary tryptamine compound of the disclosure and at least one second component selected from (a) a purified psilocybin derivative, (b) one or two purified cannabinoids or (c) a purified terpene; and at least one pharmaceutically-acceptable excipient or at least one other adjuvant, as described herein. Such a composition may be a pharmaceutical composition wherein the components are present individually in therapeutic effective amounts or by combination in a therapeutically effective amount to treat a disease, disorder, or condition as described herein.

[0167] A serotonergic drug refers to a compound that binds to, blocks, or otherwise influences (e.g., via an allosteric reaction) activity at a serotonin receptor as described in paragraphs [0245]-[0253] of US 2018/0221396 A1 and [0305]-[0311] US 2019/0142851 A1 as well as the disclosed exemplary embodiments, incorporated here by reference. Some exemplary serotonergic drugs include SSRIs and SNRIs. Some examples of specific serotonergic drugs include the following molecules, including any salts, solvates, or polymorphs thereof: 6-Allyl-N,N-diethyl-NL, N,N-Dibutyl-T, N,N-Diethyl-T, N,N-Diisopropyl-T, 5-Methyoxy-alpha-methyl-T, N,N-Dimethyl-T, 2,alpha-Dimethyl-T, alpha,N-Dimethyl-T, N,N-Dipropyl-T, N-Ethyl-N-isopropyl-T, alpha-Ethyl-T, 6,N,N-Triethyl-NL, 3,4-Dihydro-7-methoxy-1-methyl-C, 7-Methyoxy-1-methyl-C, N,N-Dibutyl-4-hydroxy-T, N,N-Diethyl-4-hydroxy-T, N,N-Diisopropyl-4-hydroxy-T, N,N-Dimethyl-4-hydroxy-T, N,N-Dimethyl-5-hydroxy-T, N, N-Dipropyl-4-hydroxy-T, N-Ethyl-4-hydroxy-N-methyl-T, 4-Hydroxy-N-isopropyl-N-methyl-T, 4-Hydroxy-N-methyl-N-propyl-T, 4-Hydroxy-N,N-tetramethylene-T Ibogaine, N,N-Diethyl-L, N-Butyl-N-methyl-T, N,N-Diisopropyl-4,5-methylenedioxy-T, N,N-Diisopropyl-5,6-methylenedioxy-T, N,N-Dimethyl-4,5-methylenedioxy-T, N,N-Dimethyl-5,6-methylenedioxy-T, N-Isopropyl-N-methyl-5,6-methylenedioxy-T, N,N-Diethyl-2-methyl-T, 2,N,N-Trimethyl-T, N-Acetyl-5-methoxy-T, N,N-Diethyl-5-methoxy-T, N,N-Diisopropyl-5-methoxy-T, 5-Methoxy-N,N-dimethyl-T, N-Isopropyl-4-methoxy-N-methyl-T, N-Isopropyl-5-methoxy-N-methyl-T, 5,6-Dimethoxy-N-isopropyl-N-methyl-T, 5-Methoxy-N-methyl-T, 5-Methoxy-N,N-tetramethylene-T, 6-Methoxy-1-methyl-1,2,3,4-tetrahydro-C, 5-Methoxy-2,N,N-trimethyl-T, N,N-Dimethyl-5-methylthio-T, N-Isopropyl-N-methyl-T, alpha-Methyl-T, N-Ethyl-T, N-Methyl-T, 6-Propyl-N L, N,N-Tetramethylene-T, Tryptamine, and 7-Methoxy-1-methyl-1,2,3,4-tetrahydro-C, alpha,N-Dimethyl-5-methoxy-T. For additional information regarding these compounds see Shulgin, A. T., & Shulgin, A. (2016). Tihkal: The Continuation. Berkeley, Calif.: Transform Press. In one embodiment, a serotonergic drug is chosen from alprazolam, amphetamine, aripiprazole, azapirone, a barbiturate, bromazepam, bupropion, buspirone, a cannabinoid, chlordiazepoxide, citalopram, clonazepam, clorazepate, dextromethorphan, diazepam, duloxetine, escitalopram, fluoxetine, flurazepam, fluvoxamine, lorazepam, lysergic acid diethylamide, lysergamide, 3,4-methylenedioxymethamphetamine, milnacipran, mirtazapine, naratriptan, paroxetine, pethidine, phenethylamine, psicaine, oxazepam, reboxetine, serenic, serotonin, sertraline, temazepam, tramadol, triazolam, a tryptamine, venlafaxine, vortioxetine, and/or derivatives thereof. In an exemplary embodiment, the serotonergic drug is 3,4-methylenedioxymethamphetamine.

[0168] Exemplary psilocybin derivatives include but are not limited to psilocybin itself and the psilocybin derivates described in paragraphs [0081]-[0109] of US 2018/0221396 A1 and [082]-[0110] US 2019/0142851 A1 as well as the disclosed exemplary embodiments, incorporated here by reference. In one embodiment, the compositions disclosed herein comprise one or more purified psilocybin derivatives chosen from: [3-(2-Dimethylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate, 4-hydroxytryptamine, 4-hydroxy-N,N-dimethyltryptamine, [3-(2-methylaminoethyl)-1H-indol-4-yl]dihydrogen phosphate, 4-hydroxy-N-methyltryptamine, [3-(aminoethyl)-1H-indol-4-yl] dihydrogen phosphate, [3-(2-trimethylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate, and 4-hydroxy-N,N,N-trimethyltryptamine.

[0169] Exemplary cannabinoids include but are not limited to the cannabinoids described in paragraphs [0111]-[0159] of US 2018/0221396 A1 and [0112]-[0160] US 2019/0142851 A1 as well as the disclosed exemplary embodiments, incorporated here by reference. Examples of cannabinoids within the context of this disclosure include the following molecules: Cannabichromene (CBC), Cannabichromenic acid (CBCA), Cannabichromevarin (CBCV), Cannabichromevarinic acid (CBCVA), Cannabicyclol (CBL), Cannabicyclolic acid (CBLA), Cannabicyclovarin (CBLV), Cannabidiol (CBD), Cannabidiol monomethylether (CBDM), Cannabidiolic acid (CBDA), Cannabidiorcol (CBD-C1), Cannabidivarin (CBDV), Cannabidivarinic acid (CBDVA), Cannabielsoic acid B (CBEA-B), Cannabielsoin (CBE), Cannabielsoin acid A (CBEA-A), Cannabigerol (CBG), Cannabigerol monomethylether (CBGM), Cannabigerolic acid (CBGA), Cannabigerolic acid monomethylether (CBGAM), Cannabigerovarin (CBGV), Cannabigerovarinic acid (CBGVA), Cannabinodiol (CBND), Cannabinodivarin (CBDV), Cannabinol (CBN), Cannabinol methylether (CBNM), Cannabinol-C2 (CBN-C2), Cannabinol-C4 (CBN-C4), Cannabinolic acid (CBNA), Cannabiorcool (CBN-C1), Cannabivarin (CBV), Cannabitriol (CBT), Cannabitriolvarin (CBTV), 10-Ethoxy-9-hydroxy-delta-6a-tetrahydrocannabinol, Cannbicitran (CBT), Cannabiripsol (CBR), 8,9-Dihydroxy-delta-6a-tetrahydrocannabinol, Delta-8-tetrahydrocannabinol (A8-THC), Delta-8-tetrahydrocannabinolic acid (A8-THCA), Delta-9-tetrahydrocannabinol (THC), Delta-9-tetrahydrocannabinol-C4 (THC-C4), Delta-9-tetrahydrocannabinolic acid A (THCA-A), Delta-9-tetrahydrocannabinolic acid B (THCA-B), Delta-9-tetrahydrocannabinolic acid-C4 (THCA-C4), Delta-9-tetrahydrocannabiorcol (THC-C1), Delta-9-tetrahydrocannabiorcolic acid (THCA-C1), Delta-9-tetrahydrocannabivarin (THCV), Delta-9-tetrahydrocannabivarinic acid (THCVA), 10-Oxo-delta-6a-tetrahydrocannabinol (OTHC), Cannabichromanon (CBCF), Cannabifuran (CBF), Cannabiglendol, Delta-9-cis-tetrahydrocannabinol (cis-THC), Tryhydroxy-delta-9-tetrahydrocannabinol (triOH-THC), Dehydrocannabifuran (DCBF), and 3,4,5,6-Tetrahydro-7-hydroxy-alpha-alpha-2-trimethyl-9-n-propyl-2,6-metha-no-2H-1-benzoxocin-5-methanol. In one embodiment, the purified cannabinoid is chosen from THC, THCA, THCV, THCVA, CBC, CBCA, CBCV, CBCVA, CBD, CBDA, CBDV, CBDVA, CBG, CBGA, CBGV, or CBGVA.

[0170] Exemplary terpenes include but are not limited to the terpenes described in paragraphs [0160]-[0238] of US 2018/0221396 A1 and [0161]-[0300] US 2019/0142851 A1 as well as the disclosed exemplary embodiments, incorporated here by reference. In one embodiment, a purified terpene is chosen from acetanisole, acetyl cedrene, anethole, anisole, benzaldehyde, bornyl acetate, borneol, cadinene, cafestol, caffeic acid, camphene, camphor, capsaicin, carene, carotene, carvacrol, carvone, caryophyllene, caryophyllene, caryophyllene oxide, cedrene, cedrene epoxide, cecanal, cedrol, cembrene, cinnamaldehyde, cinnamic acid, citronellal, citronellol, cymene, eicosane, elemene, estragole, ethyl acetate, ethyl cinnamate, ethyl maltol, eucalyptol/1,8-cineole, eudesmol, eugenol, euphol, farnesene, farnesol, fenchone, geraniol, geranyl acetate, guaia-1(10),11-diene, guaiacol, guaiol, guaiene, gurjunene, herniarin, hexanaldehyde, hexanoic acid, humulene, ionone, ipsdienol, isoamyl acetate, isoamyl alcohol, isoamyl formate, isoborneol, isomyrcenol, isoprene, isopulegol, isovaleric acid, lavandulol, limonene, gamma-linolenic acid, linalool, longifolene, lycopene, menthol, methyl butyrate, 3-mercapto-2-methylpentanal, beta-mercaptoethanol, mercaptoacetic acid, methyl salicylate, methylbutenol, methyl-2-methylvalerate, methyl thiobutyrate, myrcene, gamma-muurolene, nepetalactone, nerol, nerolidol, neryl acetate, nonanaldehyde, nonanoic acid, ocimene, octanal, octanoic acid, pentyl butyrate, phellandrene, phenylacetaldehyde, phenylacetic acid, phenylethanethiol, phytol, pinene, propanethiol, pristimerin, pulegone, retinol, rutin, sabinene, squalene, taxadiene, terpineol, terpine-4-ol, terpinolene, thujone, thymol, umbelliferone, undecanal, verdoxan, or vanillin. In one embodiment, a purified terpene is chosen from bornyl acetate, alpha-bisabolol, borneol, camphene, camphor, carene, caryophyllene, cedrene, cymene, elemene, eucalyptol, eudesmol, farnesene, fenchol, geraniol, guaiacol, humulene, isoborneol, limonene, linalool, menthol, myrcene, nerolidol, ocimene, phellandrene, phytol, pinene, pulegone, sabinene, terpineol, terpinolene, or valencene.

[0171] As used herein, the term adrenergic drug refers to a compound that binds, blocks, or otherwise influences (e.g., via an allosteric reaction) activity at an adrenergic receptor. In one embodiment, an adrenergic drug binds to an adrenergic receptor. In one embodiment, an adrenergic drug indirectly affects an adrenergic receptor, e.g., via interactions affecting the reactivity of other molecules at the adrenergic receptor. In one embodiment, an adrenergic drug is an agonist, e.g., a compound activating an adrenergic receptor. In one embodiment, an adrenergic drug is an antagonist, e.g., a compound binding but not activating an adrenergic receptor, e.g., blocking a receptor. In one embodiment, an adrenergic drug is an effector molecule, e.g., a compound binding to an enzyme for allosteric regulation. In one embodiment, an adrenergic drug acts (either directly or indirectly) at more than one type of receptor (e.g., 5HT, dopamine, adrenergic, acetylcholine, etc.).

[0172] In one embodiment, an adrenergic drug is an antidepressant. In one embodiment, an adrenergic drug is a norepinephrine transporter inhibitor. In one embodiment, an adrenergic drug is a vesicular monoamine transporter inhibitor. In one embodiment, an adrenergic drug is chosen from adrenaline, agmatine, amoxapine, aptazapine, atomoxetine, bupropion, clonidine, doxepin, duloxetine, esmirtazpine, mianserin, ketanserin, mirabegron, mirtazapine, norepinephrine, phentolamine, phenylephrine, piperoxan, reserpine, ritodrine, setiptiline, tesofensine, timolol, trazodone, trimipramine, or xylazine.

[0173] As used herein, the term dopaminergic drug refers to a compound that binds, blocks, or otherwise influences (e.g., via an allosteric reaction) activity at a dopamine receptor. In one embodiment, a dopaminergic drug binds to a dopamine receptor. In one embodiment, a dopaminergic drug indirectly affects a dopamine receptor, e.g., via interactions affecting the reactivity of other molecules at the dopamine receptor. In one embodiment, a dopaminergic drug is an agonist, e.g., a compound activating a dopamine receptor. In one embodiment, a dopaminergic drug is an antagonist, e.g., a compound binding but not activating a dopamine receptor, e.g., blocking a receptor. In one embodiment, a dopaminergic drug is an effector molecule, e.g., a compound binding to an enzyme for allosteric regulation. In one embodiment, a dopaminergic drug acts (either directly or indirectly) at more than one type of receptor (e.g., 5HT, dopamine, adrenergic, acetylcholine, etc.).

[0174] In one embodiment, a dopaminergic drug is a dopamine transporter inhibitor. In one embodiment, a dopaminergic drug is a vesicular monoamine transporter inhibitor. In one embodiment, a dopaminergic drug is chosen from amineptine, apomorphine, benzylpiperazine, bromocriptine, cabergoline, chlorpromazine, clozapine, dihydrexidine, domperidone, dopamine, fluphenazine, haloperidol, ketamine, loxapine, methamphetamine, olanzapine, pemoline, perphenazine, pergolide, phencyclidine, phenethylamine, phenmetrazine, pimozide, piribedil, a psychostimulant, reserpine, risperidone, ropinirole, tetrabenazine, or thioridazine.

[0175] As used herein, the term monoamine oxidase inhibitor (MAOI) refers to a compound that blocks the actions of monoamine oxidase enzymes. In on embodiment, a MAOI inhibits the activity of one or both monoamine oxidase A and monoamine oxidase B. In one embodiment a MAOI is a reversible inhibitors of monoamine oxidase A. In one embodiment a MAOI is a drug chosen from isocarboxazid, phenelzine, or tranylcypromine.

[0176] In one embodiment, the compositions and methods disclosed herein include one or more purified erinacine molecules. In one embodiment, the compositions and methods disclosed herein comprise purified erinacine A. In one embodiment, the compositions and methods disclosed herein comprise erinacine B. In one embodiment, the compositions and methods disclosed herein comprise erinacine C. In one embodiment, the compositions and methods disclosed herein comprise erinacine D. In one embodiment, the compositions and methods disclosed herein comprise erinacine E. In one embodiment, the compositions and methods disclosed herein comprise erinacine F. In one embodiment, the compositions and methods disclosed herein comprise erinacine G. In one embodiment, the compositions and methods disclosed herein comprise erinacine H. In one embodiment, the compositions and methods disclosed herein comprise erinacine I. In one embodiment, the compositions and methods disclosed herein comprise erinacine J. In one embodiment, the compositions and methods disclosed herein comprise erinacine K In one embodiment, the compositions and methods disclosed herein comprise erinacine P. In one embodiment, the compositions and methods disclosed herein comprise erinacine Q. In one embodiment, the compositions and methods disclosed herein comprise erinacine R. In one embodiment, the compositions and methods disclosed herein comprise erinacine S.

[0177] In one embodiment, the compositions and methods disclosed herein include one or more purified hericenone molecules. In one embodiment, the compositions and methods disclosed herein comprise purified hericenone A. In one embodiment, the compositions and methods disclosed herein comprise purified hericenone B. In one embodiment, the compositions and methods disclosed herein comprise purified hericenone C. In one embodiment, the compositions and methods disclosed herein comprise purified hericenone D. In one embodiment, the compositions and methods disclosed herein comprise purified hericenone E. In one embodiment, the compositions and methods disclosed herein comprise purified hericenone F. In one embodiment, the compositions and methods disclosed herein comprise purified hericenone G. In one embodiment, the compositions and methods disclosed herein comprise purified hericenone H.

[0178] Exemplary compositions of a quaternary tryptamine compound of the disclosure, for example a compound of formula (I) or a compound of formula (II), and a second compound selected from a serotonergic drug, a purified psilocybin derivative, a purified cannabinoid, a purified terpene, an adrenergic drug, a dopaminergic drug, a monoamine oxidase inhibitor, a purified erinacine, or a purified hericenone in exemplary molar ratios are shown in Table 6. A quaternary tryptamine compound of the disclosure may be any one of the exemplary embodiments described above; with the proviso that for a compound of formula (II) when R.sub.1, R.sub.2, and R.sub.3 are methyl and R.sub.4, R.sub.7, R.sub.8, R.sub.9, R.sub.10, and R.sub.11 are hydrogen, R.sub.6 is not Br.

TABLE-US-00006 TABLE 6 Molar ratio of a Molar ratio of a Molar ratio of a quaternary quaternary quaternary tryptamine tryptamine tryptamine compound of the compound of the compound of the disclosure:second disclosure:second disclosure: second Second Compound compound compound compound 3,4- About 1:100 to About 1:25 to About 1:5 to methylenedioxymethamphetamine about 100:1 about 25:1 about 5:1 Citalopram About 1:100 to About 1:25 to About 1:5 to about 100:1 about 25:1 about 5:1 Escitalopram About 1:100 to About 1:25 to About 1:5 to about 100:1 about 25:1 about 5:1 Fluoxetine About 1:100 to About 1:25 to About 1:5 to about 100:1 about 25:1 about 5:1 Paroxetine About 1:100 to About 1:25 to About 1:5 to about 100:1 about 25:1 about 5:1 Sertraline About 1:100 to About 1:25 to About 1:5 to about 100:1 about 25:1 about 5:1 [3-(2-Dimethylaminoethyl)-1H- About 1:100 to About 1:25 to About 1:5 to indol-4-yl] dihydrogen phosphate about 100:1 about 25:1 about 5:1 4-hydroxytryptamine About 1:100 to About 1:25 to About 1:5 to about 100:1 about 25:1 about 5:1 4-hydroxy-N,N-dimethyltryptamine About 1:100 to About 1:25 to About 1:5 to about 100:1 about 25:1 about 5:1 [3-(2-methylaminoethyl)-1H-indol- About 1:100 to About 1:25 to About 1:5 to 4-yl] dihydrogen phosphate about 100:1 about 25:1 about 5:1 4-hydroxy-N-methyltryptamine About 1:100 to About 1:25 to About 1:5 to about 100:1 about 25:1 about 5:1 [3-(aminoethyl)-1H-indol-4-yl] About 1:100 to About 1:25 to About 1:5 to dihydrogen phosphate about 100:1 about 25:1 about 5:1 [3-(2-trimethylaminoethyl)-1H- About 1:100 to About 1:25 to About 1:5 to indol-4-yl] dihydrogen phosphate about 100:1 about 25:1 about 5:1 4-hydroxy-N,N,N- About 1:100 to About 1:25 to About 1:5 to trimethyltryptamine about 100:1 about 25:1 about 5:1 THC About 1:100 to About 1:25 to About 1:5 to about 100:1 about 25:1 about 5:1 CBC About 1:100 to About 1:25 to About 1:5 to about 100:1 about 25:1 about 5:1 CBD About 1:100 to About 1:25 to About 1:5 to about 100:1 about 25:1 about 5:1 CBG About 1:100 to About 1:25 to About 1:5 to about 100:1 about 25:1 about 5:1 Myrcene About 1:100 to About 1:25 to About 1:5 to about 100:1 about 25:1 about 5:1 Pinene About 1:100 to About 1:25 to About 1:5 to about 100:1 about 25:1 about 5:1 Caryophyllene About 1:100 to About 1:25 to About 1:5 to about 100:1 about 25:1 about 5:1 Limonene About 1:100 to About 1:25 to About 1:5 to about 100:1 about 25:1 about 5:1 Humulene About 1:100 to About 1:25 to About 1:5 to about 100:1 about 25:1 about 5:1 Linalool About 1:100 to About 1:25 to About 1:5 to about 100:1 about 25:1 about 5:1 Adrenaline About 1:100 to About 1:25 to About 1:5 to about 100:1 about 25:1 about 5:1 Amineptine About 1:100 to About 1:25 to About 1:5 to about 100:1 about 25:1 about 5:1 Erinacine A About 1:100 to About 1:25 to About 1:5 to about 100:1 about 25:1 about 5:1 Hericenone A About 1:100 to About 1:25 to About 1:5 to about 100:1 about 25:1 about 5:1 Phenelzine About 1:100 to About 1:25 to About 1:5 to about 100:1 about 25:1 about 5:1

[0179] Exemplary pharmaceutical compositions of a quaternary tryptamine compound of the disclosure, for example a compound of formula (I) or a compound of formula (II), and a second compound selected from a serotonergic drug, a purified psilocybin derivative, a purified cannabinoid, a purified terpene, an adrenergic drug, a dopaminergic drug, a monoamine oxidase inhibitor, a purified erinacine, or a purified hericenone and an excipient with exemplary molar ratios of a quaternary tryptamine compound of the disclosure to the second compound are shown in Table 7. A quaternary tryptamine compound of the disclosure may be any one of the exemplary embodiments described above; with the proviso that for a compound of formula (II) when R.sub.1, R.sub.2, and R.sub.3 are methyl and R.sub.4, R.sub.7, R.sub.8, R.sub.9, R.sub.10, and R.sub.11 are hydrogen, R.sub.6 is not Br.

TABLE-US-00007 TABLE 7 Molar ratio of a Molar ratio of a Molar ratio of a quaternary quaternary quaternary tryptamine tryptamine tryptamine compound of the compound of the compound of the disclosure:second disclosure:second disclosure:second Second Compound compound compound compound 3,4- About 1:100 to About 1:25 to About 1:5 to methylenedioxymethamphetamine about 100:1 about 25:1 about 5:1 Citalopram About 1:100 to About 1:25 to About 1:5 to about 100:1 about 25:1 about 5:1 Escitalopram About 1:100 to About 1:25 to About 1:5 to about 100:1 about 25:1 about 5:1 Fluoxetine About 1:100 to About 1:25 to About 1:5 to about 100:1 about 25:1 about 5:1 Paroxetine About 1:100 to About 1:25 to About 1:5 to about 100:1 about 25:1 about 5:1 Sertraline About 1:100 to About 1:25 to About 1:5 to about 100:1 about 25:1 about 5:1 [3-(2-Dimethylaminoethyl)-1H- About 1:100 to About 1:25 to About 1:5 to indol-4-yl] dihydrogen phosphate about 100:1 about 25:1 about 5:1 4-hydroxytryptamine About 1:100 to About 1:25 to About 1:5 to about 100:1 about 25:1 about 5:1 4-hydroxy-N,N-dimethyltryptamine About 1:100 to About 1:25 to About 1:5 to about 100:1 about 25:1 about 5:1 [3-(2-methylaminoethyl)-1H-indol- About 1:100 to About 1:25 to About 1:5 to 4-yl] dihydrogen phosphate about 100:1 about 25:1 about 5:1 4-hydroxy-N-methyltryptamine About 1:100 to About 1:25 to About 1:5 to about 100:1 about 25:1 about 5:1 [3-(aminoethyl)-1H-indol-4-yl] About 1:100 to About 1:25 to About 1:5 to dihydrogen phosphate about 100:1 about 25:1 about 5:1 [3-(2-trimethylaminoethyl)-1H- About 1:100 to About 1:25 to About 1:5 to indol-4-yl] dihydrogen phosphate about 100:1 about 25:1 about 5:1 4-hydroxy-N,N,N- About 1:100 to About 1:25 to About 1:5 to trimethyltryptamine about 100:1 about 25:1 about 5:1 THC About 1:100 to About 1:25 to About 1:5 to about 100:1 about 25:1 about 5:1 CBC About 1:100 to About 1:25 to About 1:5 to about 100:1 about 25:1 about 5:1 CBD About 1:100 to About 1:25 to About 1:5 to about 100:1 about 25:1 about 5:1 CBG About 1:100 to About 1:25 to About 1:5 to about 100:1 about 25:1 about 5:1 Myrcene About 1:100 to About 1:25 to About 1:5 to about 100:1 about 25:1 about 5:1 Pinene About 1:100 to About 1:25 to About 1:5 to about 100:1 about 25:1 about 5:1 Caryophyllene About 1:100 to About 1:25 to About 1:5 to about 100:1 about 25:1 about 5:1 Limonene About 1:100 to About 1:25 to About 1:5 to about 100:1 about 25:1 about 5:1 Humulene About 1:100 to About 1:25 to About 1:5 to about 100:1 about 25:1 about 5:1 Linalool About 1:100 to About 1:25 to About 1:5 to about 100:1 about 25:1 about 5:1 Adrenaline About 1:100 to About 1:25 to About 1:5 to about 100:1 about 25:1 about 5:1 Amineptine About 1:100 to About 1:25 to About 1:5 to about 100:1 about 25:1 about 5:1 Erinacine A About 1:100 to About 1:25 to About 1:5 to about 100:1 about 25:1 about 5:1 Hericenone A About 1:100 to About 1:25 to About 1:5 to about 100:1 about 25:1 about 5:1 Phenelzine About 1:100 to About 1:25 to About 1:5 to about 100:1 about 25:1 about 5:1

[0180] An effective amount or a therapeutically effective amount of a quaternary tryptamine compound of the disclosure is generally in the range of about 0.1 to about 100 mg daily (oral dose), of about 0.1 to about 50 mg daily (oral dose) of about 0.25 to about 25 mg daily (oral dose), of about 0.1 to about 5 mg daily (oral dose) or of about 0.5 to about 2.5 mg daily (oral dose). The actual amount required for treatment of any particular patient may depend upon a variety of factors including, for example, the disease being treated and its severity; the specific pharmaceutical composition employed; the age, body weight, general health, sex, and diet of the patient; the mode of administration; the time of administration; the route of administration; and the rate of excretion; the duration of the treatment; any drugs used in combination or coincidental with the specific compound employed; and other such factors well known in the medical arts. These factors are discussed in Goodman and Gilman's The Pharmacological Basis of Therapeutics, Tenth Edition, A. Gilman, J. Hardman and L. Limbird, eds., McGraw-Hill Press, 155-173 (2001), which is incorporated herein by reference. A quaternary tryptamine compound of the disclosure and pharmaceutical compositions containing it may be used in combination with other agents that are generally administered to a patient being treated for psychological and other disorders discussed above. They may also be co-formulated with one or more of such agents in a single pharmaceutical composition.

[0181] Depending on the type of pharmaceutical composition, the pharmaceutically acceptable carrier may be chosen from any one or a combination of carriers known in the art. The choice of the pharmaceutically acceptable carrier depends upon the pharmaceutical form and the desired method of administration to be used. Exemplary carriers include those that do not substantially alter the structure or activity of the quaternary tryptamine compounds of the disclosure or produce undesirable biological effects or otherwise interact in a deleterious manner with any other component(s) of the pharmaceutical composition.

[0182] The pharmaceutical compositions of the disclosure may be prepared by methods know in the pharmaceutical formulation art, for example, see Remington's Pharmaceutical Sciences, 18th Ed., (Mack Publishing Company, Easton, Pa., 1990), which is incorporated herein by reference. In a solid dosage form, a quaternary tryptamine compound of the disclosure may be admixed with at least one pharmaceutically acceptable excipient such as, for example, sodium citrate or dicalcium phosphate or (a) fillers or extenders, such as, for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid, (b) binders, such as, for example, cellulose derivatives, starch, alignates, gelatin, polyvinylpyrrolidone, sucrose, and gum acacia, (c) humectants, such as, for example, glycerol, (d) disintegrating agents, such as, for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, croscarmellose sodium, complex silicates, and sodium carbonate, (e) solution retarders, such as, for example, paraffin, (f) absorption accelerators, such as, for example, quaternary ammonium compounds, (g) wetting agents, such as, for example, cetyl alcohol, and glycerol monostearate, magnesium stearate and the like, (h) adsorbents, such as, for example, kaolin and bentonite, and (i) lubricants, such as, for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents. In some embodiments, the excipient is not water. In some embodiments, the excipient is not a solvent (e.g., EtOH, diethyl ether, ethyl acetate, or hydrocarbon-based solvents (e.g., hexanes). In some embodiments, the dosage form is substantially free of water and/or solvents, for example less than about 5% water by mass, less than 2% water by mass, less than 1% water by mass, less than 0.5% water by mass, or less than 0.1% water by mass.

[0183] Excipients or pharmaceutically acceptable adjuvants known in the pharmaceutical formulation art may also be used in the pharmaceutical compositions of the disclosure. These include, but are not limited to, preserving, wetting, suspending, sweetening, flavoring, perfuming, emulsifying, and dispensing agents. Prevention of the action of microorganisms may be ensured by inclusion of various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, for example, sugars, sodium chloride, and the like. If desired, a pharmaceutical composition of the disclosure may also contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, antioxidants, and the like, such as, for example, citric acid, sorbitan monolaurate, triethanolamine oleate, butylated hydroxytoluene, etc.

[0184] Solid dosage forms as described above may be prepared with coatings and shells, such as enteric coatings and others well known in the art. They may contain pacifying agents and can also be of such composition that they release the active compound or compounds in a certain part of the intestinal tract in a delayed manner. Non-limiting examples of embedded compositions that may be used are polymeric substances and waxes. The active compounds may also be in microencapsulated form, if appropriate, with one or more of the above-mentioned excipients.

[0185] Suspensions, in addition to the active compounds, may contain suspending agents, such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances, and the like.

[0186] Solid dosage forms for oral administration, which includes capsules, tablets, pills, powders, and granules, may be used. In such solid dosage forms, the active compound may be mixed with at least one inert, pharmaceutically acceptable excipient (also known as a pharmaceutically acceptable carrier).

[0187] Administration of a quaternary tryptamine compound of the disclosure in pure form or in an appropriate pharmaceutical composition may be carried out via any of the accepted modes of administration or agents for serving similar utilities. Thus, administration may be, for example, orally, buccally, nasally, parenterally (intravenous, intramuscular, or subcutaneous), topically, transdermally, intravaginally, intravesically, or intrasystemically, in the form of solid, semi-solid, lyophilized powder, or liquid dosage forms, such as, for example, tablets, suppositories, pills, soft elastic and hard gelatin capsules, powders, solutions, suspensions, or aerosols, or the like, such as, for example, in unit dosage forms suitable for simple administration of precise dosages. One route of administration may be oral administration, using a convenient daily dosage regimen that can be adjusted according to the degree of severity of the disease-state to be treated.

EXAMPLES

[0188] The preparation of compounds of formula (II), including crystalline 5-F-TMT iodide, crystalline 5-F-TET iodide, crystalline 5-F-TPT iodide, crystalline 5-Cl-TMT iodide, crystalline 5-Cl-TET iodide, crystalline 5-Br-TET iodide, crystalline 5-Br-TPT iodide, and crystalline 5-Br-TPT iodide acetonitrile solvate are described below.

Example 1: Synthesis and Crystallization of 5-fluoro-N,N,N-trimethyltryptammonium (5-F-TMT) iodide

[0189] 146 mg of 5-fluorotryptamine was dissolved in 10 mL of isopropanol, and 261 mg of sodium carbonate and 0.4 mL of iodomethane were then added. The mixture was refluxed under nitrogen for 24 hrs. Solvent was removed in vacuo to yield an orange powder. The powder was washed with water and isolated via vacuum filtration. The powder was washed in diethyl ether and dried under vacuum. 130 mg of light-yellow powder was collected (45% yield). Crystal suitable for X-ray diffraction studies were grown from the slow evaporation of an acetone solution.

[0190] .sup.1H NMR (400 MHz, CDCl.sub.3): 7.48 (q, J=4.4 Hz, 1H, ArH), 7.39-7.36 (m, 2H, ArH), 7.09-7.03 (m, 1H, ArH), 3.65-3.61 (m, 2H, CH.sub.2), 3.32-3.28 (m, 2H, CH.sub.2), 3.23 (s, 9H, CH.sub.3).

[0191] Single crystal data, data collection and structure refinement details of crystalline 5-F-TMT iodide are summarized in Table 8.

TABLE-US-00008 TABLE 8 5-fluoro-N,N,N-trimethyltryptammonium iodide Chemical formula IC.sub.13H.sub.18FN.sub.2 M.sub.r 348.19 Crystal system, space group Orthorhombic, P2.sub.12.sub.12.sub.1 Temperature (K) 297 a, b, c () 7.7261 (4), 13.6571 (6), 13.9972 (7) V (.sup.3) 1476.93 (12) Z 4 F(000) 688 D.sub.x (Mg m.sup.3) 1.566 Radiation type M.sub.o K.sub. () 0.71073 () 2.9-26.0 (mm.sup.1) 2.16 Crystal size (mm) 0.24 0.08 0.06 PLATE Colourless Diffractometer Bruker D8 Venture CMOS Absorption correction Multi-scan SADABS2016/2 (Bruker, 2016/2) was used for absorption correction. wR2(int) was 0.0632 before and 0.0541 after correction. The Ratio of minimum to maximum transmission is 0.8834. The /2 correction factor is not present. T.sub.min, T.sub.max 0.659, 0.745 No. of measured, independent, and 28378, 2998, 2360 observed [I > 2s(I)] reflections R.sub.int 0.043 .sub.max, .sub.min () 26.4, 2.9 h, k, l 9.fwdarw.9, 16.fwdarw.17, 17.fwdarw.17 Refinement F.sup.2 R[F.sup.2 > 2(F.sup.2)], wR(F.sup.2), S 0.028, 0.073, 1.13 w 1/[.sup.2(F.sub.o.sup.2) + (0.0217P).sup.2 + 1.1374P] where P = (F.sub.o.sup.2 + 2F.sub.c.sup.2)/3 No. of reflections 2998 No. of parameters 161 No. of restraints 1 H-site location mixed H-atom treatment H atoms treated by a mixture of independent and constrained refinement (/).sub.max 0.001 >.sub.max, >.sub.min (e .sup.3) 0.56, 0.63 Absolute Structure Refined as an inversion twin Absolute Structure Parameter 0.10 (5)

[0192] Data collection: Bruker APEX3; cell refinement: Bruker SAINT; data reduction: Bruker SAINT; program(s) used to solve structure: SHELXS97 (Sheldrick 2008); program(s) used to refine structure: SHELXL 2018/3 (Sheldrick, 2015); molecular graphics: Olex2 1.3 (Dolomanov et al., 2009); software used to prepare material for publication: Olex2 1.3 (Dolomanov et al., 2009).

[0193] The molecular structure of crystalline 5-F-TMT iodide, showing the atom labeling, is shown in FIG. 1.

[0194] FIG. 2 is a simulated x-ray powder diffraction (XRPD) of crystalline 5-F-TMT iodide from its single crystal data. Crystalline 5-F-TMT iodide may be characterized by the XRPD peaks at 13.1, 20.5, and 22.220.22 as well as by an XRPD pattern substantially similar to FIG. 2.

Example 2: Synthesis and Crystallization of 5-fluoro-N,N,N-triethyltryptammonium (5-F-TET) iodide

[0195] 143 mg of 5-Fluoro Tryptamine was dissolved in 10 mL of isopropanol, 256 mg of Na.sub.2CO.sub.3 and 0.5 mL of Ethyl Iodide were then added. The mixture was refluxed under nitrogen for 24 hrs. The solvent was stripped off on a rotovap, orange powder was obtained. The powder was washed in DI water then filtered under vacuum. The powder was washed again in ether then placed under vacuum for 2 days. 180 mg of light-yellow powder was collected.

[0196] The percent yield was calculated as 58.08%.

[0197] .sup.1H NMR (400 MHz, CDCl.sub.3): 7.49 (q, J=4.5 Hz, 1H, ArH), 7.37-7.33 (m, 2H, ArH), 7.09-7.04 (m, 1H, ArH), 3.44-3.37 (m, 8H, CH.sub.2), 3.18-3.14 (m, 2H, CH.sub.2), 1.33 (t, J=7.2 Hz, 9H, CH.sub.3).

[0198] Single crystal data, data collection and structure refinement details of crystalline 5-F-TET iodide are summarized in Table 9.

TABLE-US-00009 TABLE 9 5-fluoro-N,N,N-triethyltryptammonium iodide Chemical formula IC.sub.16H.sub.24FN.sub.2 M.sub.r 390.27 Crystal system, space group Orthorhombic, P2.sub.12.sub.12.sub.1 Temperature (K) 297 a, b, c () 8.5885 (4), 13.6650 (6), 14.6306 (7) V (.sup.3) 1717.07 (14) Z 4 F(000) 784 D.sub.x (Mg m.sup.3) 1.510 Radiation type M.sub.o K.sub. () 0.71073 () 2.8-26.4 (mm.sup.1) 1.87 Crystal size (mm) 0.22 0.18 0.14 BLOCK Colourless Diffractometer Bruker D8 Venture CMOS Absorption correction Multi-scan SADABS2016/2 (Bruker, 2016/2) was used for absorption correction. wR2(int) was 0.0600 before and 0.0475 after correction. The Ratio of minimum to maximum transmission is 0.9276. The /2 correction factor is not present. T.sub.min, T.sub.max 0.691, 0.745 No. of measured, independent, and 53582, 3468, 3410 observed [I > 2s(I)] reflections R.sub.int 0.023 .sub.max, .sub.min () 26.4, 3.2 h, k, l 10.fwdarw.10, 16.fwdarw.17, 18.fwdarw.18 Refinement F.sup.2 R[F.sup.2 > 2(F.sup.2)], wR(F.sup.2), S 0.015, 0.037, 1.09 w 1/[.sup.2(F.sub.o.sup.2) + (0.0147P).sup.2 + 0.4873P] where P = (F.sub.o.sup.2 + 2F.sub.c.sup.2)/3 No. of reflections 3468 No. of parameters 188 No. of restraints 0 H-site location mixed H-atom treatment H atoms treated by a mixture of independent and constrained refinement (/).sub.max 0.002 >.sub.max, >.sub.min (e .sup.3) 0.27, 0.29 Absolute Structure Flack x determined using 1445 quotients Absolute Structure Parameter [(I+) (I)]/[(I+) + (I)] (Parsons, Flack and Wagner, Acta Cryst. B69 (2013) 249-259). Absolute Structure Parameter 0.014 (4)

[0199] Data collection: Bruker APEX3; cell refinement: Bruker SAINT; data reduction: Bruker SAINT; program(s) used to solve structure: SHELXS97 (Sheldrick 2008); program(s) used to refine structure: SHELXL 2018/3 (Sheldrick, 2015); molecular graphics: Olex2 1.3 (Dolomanov et al., 2009); software used to prepare material for publication: Olex2 1.3 (Dolomanov et al., 2009).

[0200] The molecular structure of crystalline 5-F-TET iodide, showing the atom labeling, is shown in FIG. 3.

[0201] FIG. 4 is a simulated x-ray powder diffraction (XRPD) of crystalline 5-F-TET iodide from its single crystal data. Crystalline 5-F-TET iodide may be characterized by the XRPD peaks at 13.6, 15.9, and 16.620.22 as well as by an XRPD pattern substantially similar to FIG. 4.

Example 3: Synthesis and Crystallization of 5-fluoro-N,N,N-tri-n-propyltryptammonium (5-F-TPT) iodide

[0202] 5-F-TPT iodide was synthesized via the same procedure used in Example 1 but substituting propyl iodide for methyl iodide.

[0203] Single crystal data, data collection and structure refinement details of crystalline 5-F-TPT iodide are summarized in Table 10.

TABLE-US-00010 TABLE 10 5-fluoro-N,N,N-tri-n-propyltryptammonium iodide Chemical formula IC.sub.19H.sub.30FN.sub.2 M.sub.r 432.35 Crystal system, space group Monoclinic, P2.sub.1/c Temperature (K) 297 a, b, c () 17.8375 (9), 7.4586 (3), 16.4361 (7) () 110.228 (2) V (.sup.3) 2051.84 (16) Z 4 F(000) 880 D.sub.x (Mg m.sup.3) 1.400 Radiation type M.sub.o K.sub. () 0.71073 () 2.9-26.3 (mm.sup.1) 1.57 Crystal size (mm) 0.26 0.2 0.1 BLOCK Colourless Diffractometer Bruker APEX-II CCD Absorption correction Multi-scan SADABS2016/2 (Bruker, 2016/2) was used for absorption correction. wR2(int) was 0.0644 before and 0.0463 after correction. The Ratio of minimum to maximum transmission is 0.8822. The /2 correction factor is not present. T.sub.min, T.sub.max 0.658, 0.745 No. of measured, independent, and 42496, 4188, 3484 observed [I > 2s(I)] reflections R.sub.int 0.033 .sub.max, .sub.min () 26.4, 2.9 h, k, l 22.fwdarw.22, 9.fwdarw.9, 20.fwdarw.20 Refinement F.sup.2 R[F.sup.2 > 2(F.sup.2)], wR(F.sup.2), S 0.038, 0.092, 1.05 w 1/[.sup.2(F.sub.o.sup.2) + (0.0308P).sup.2 + 2.9959P] where P = (F.sub.o.sup.2 + 2F.sub.c.sup.2)/3 No. of reflections 4188 No. of parameters 215 No. of restraints 0 H-site location mixed H-atom treatment H atoms treated by a mixture of independent and constrained refinement (/).sub.max 0.001 >.sub.max, >.sub.min (e .sup.3) 1.12, 0.93
Data collection: Bruker APEX3; cell refinement: Bruker SAINT; data reduction: Bruker SAINT; program(s) used to solve structure: SHELXS97 (Sheldrick 2008); program(s) used to refine structure: SHELXL 2018/3 (Sheldrick, 2015); molecular graphics: Olex2 1.3 (Dolomanov et al., 2009); software used to prepare material for publication: Olex2 1.3 (Dolomanov et al., 2009).

[0204] The molecular structure of crystalline 5-F-TPT iodide, showing the atom labeling, is shown in FIG. 5.

[0205] FIG. 6 is a simulated x-ray powder diffraction (XRPD) of crystalline 5-F-TPT iodide from its single crystal data. Crystalline 5-F-TPT iodide may be characterized by the XRPD peaks at 10.6, 13.4, and 18.120.22 as well as by an XRPD pattern substantially similar to FIG. 6.

Example 4: Synthesis and Crystallization of 5-chloro-N,N,N-trimethyltryptammonium (5-Cl-TMT) iodide

[0206] 5-Cl-TMT iodide was synthesized via the same procedure used in Example 1. This procedure was repeated using a 5-chloro tryptamine in the presence of excess iodomethane.

[0207] Single crystal data, data collection and structure refinement details of crystalline 5-Cl-TMT iodide are summarized in Table 11.

TABLE-US-00011 TABLE 11 5-chloro-N,N,N-trimethyltryptammonium iodide Chemical formula IC.sub.13H.sub.18ClN.sub.2 M.sub.r 364.64 Crystal system, space group Monoclinic, I2/ Temperature (K) 297 a, b, c () 13.5105 (15), 14.1488 (8), 15.9096 (9) () 90.3840 (13) V (.sup.3) 3041.2 (4) Z 8 F(000) 1440 D.sub.x (Mg m.sup.3) 1.593 Radiation type M.sub.o K.sub. () 0.71073 () 2.9-26.3 (mm.sup.1) 2.26 Crystal size (mm) 0.24 0.15 0.15 BLOCK Colourless Diffractometer Bruker APEX-II CCD Absorption correction Multi-scan SADABS2016/2 (Bruker, 2016/2) was used for absorption correction. wR2(int) was 0.0726 before and 0.0563 after correction. The Ratio of minimum to maximum transmission is 0.8487. The /2 correction factor is not present. T.sub.min, T.sub.max 0.549, 0.647 No. of measured, independent, and 28265, 3086, 2430 observed [I > 2s(I)] reflections R.sub.int 0.039 .sub.max, .sub.min () 26.4, 2.9 h, k, l 16.fwdarw.16, 17.fwdarw.17, 19.fwdarw.19 Refinement F.sup.2 R[F.sup.2 > 2(F.sup.2)], wR(F.sup.2), S 0.036, 0.112, 1.08 w 1/[.sup.2(F.sub.o.sup.2) + (0.0598P).sup.2 + 5.7979P] where P = (F.sub.o.sup.2 + 2F.sub.c.sup.2)/3 No. of reflections 3086 No. of parameters 161 No. of restraints 1 H-site location mixed H-atom treatment H atoms treated by a mixture of independent and constrained refinement (/).sub.max <0.001 >.sub.max, >.sub.min (e .sup.3) 0.84, 0.94
Data collection: Bruker APEX3; cell refinement: Bruker SAINT; data reduction: Bruker SAINT; program(s) used to solve structure: SHELXS97 (Sheldrick 2008); program(s) used to refine structure: SHELXL 2018/3 (Sheldrick, 2015); molecular graphics: Olex2 1.3 (Dolomanov et al., 2009); software used to prepare material for publication: Olex2 1.3 (Dolomanov et al., 2009).

[0208] The molecular structure of crystalline 5-Cl-TMT iodide, showing the atom labeling, is shown in FIG. 7.

[0209] FIG. 8 is a simulated x-ray powder diffraction (XRPD) of crystalline 5-Cl-TMT iodide from its single crystal data. Crystalline 5-Cl-TMT iodide may be characterized by the XRPD peaks at 11.1, 14.4, and 20.7 20.2 2 as well as by an XRPD pattern substantially similar to FIG. 8.

Example 5: Synthesis and Crystallization of 5-chloro-N,N,N-triethyltryptammonium (5-Cl-TET) iodide

[0210] 106 mg of 5-Chloro Tryptamine was dissolved in 10 mL of isopropanol, 146 mg of Na.sub.2CO.sub.3 and 0.3 mL of Ethyl Iodide were then added. The mixture was refluxed under nitrogen for 24 hrs. The solvent was stripped off on a rotovap, orange/yellow powder was obtained. The powder was sonicated in 3 mL of THF for 30 minutes then filtered under vacuum yielding 69 mg of white powder on the frit. This powder was then sonicated in 20 mL of Acetonitrile then filtered under vacuum. Colourless crystals were obtained upon evaporation of the Acetonitrile.

[0211] The percent yield was calculated as 77.66%.

[0212] Single crystals suitable for X-ray diffraction was obtained from slow evaporation of Acetone solution. The crystals obtained from slow evaporation of Acetonitrile had the same unit cell.

[0213] .sup.1H NMR (400 MHz, CD.sub.3CN): 9.53 (s, 1H, NH), 7.60 (d, J=2.0 Hz, 1H, ArH), 7.44 (d, J=8.7 Hz, 1H, ArH), 7.29 (d, J=2.3 Hz, 1H, ArH), 7.15 (dd, J=8.7, 2.0 Hz, 1H, ArH), 3.38-3.30 (m, 8H, CH.sub.2), 3.12-3.08 (m, 2H, CH.sub.2), 1.29 (tt, J=7.2, 1.8 Hz, 9H, CH.sub.3).

[0214] Single crystal data, data collection and structure refinement details of crystalline 5-Cl-TET iodide are summarized in Table 12.

TABLE-US-00012 TABLE 12 5-chloro-N,N,N-triethyltryptammonium iodide Chemical formula IC.sub.16H.sub.24ClN.sub.2 M.sub.r 406.72 Crystal system, space group Triclinic, P1 Temperature (K) 297 a, b, c () 12.4760 (13), 12.5317 (12), 13.9873 (16) () 75.340 (3) () 68.793 (4) () 64.486 (3) V (.sup.3) 1827.6 (3) Z 4 F(000) 816 D.sub.x (Mg m.sup.3) 1.478 Radiation type M.sub.o K.sub. () 0.71073 () 3.0-26.1 (mm.sup.1) 1.89 Crystal size (mm) 0.2 0.2 0.03 PLATE Colourless Diffractometer Bruker APEX-II CCD Absorption correction Multi-scan SADABS2016/2 (Bruker, 2016/2) was used for absorption correction. wR2(int) was 0.0556 before and 0.0447 after correction. The Ratio of minimum to maximum transmission is 0.8958. The /2 correction factor is not present. T.sub.min, T.sub.max 0.668, 0.745 No. of measured, independent, and 47765, 7503, 6059 observed [I > 2s(I)] reflections R.sub.int 0.035 .sub.max, .sub.min () 26.5, 2.5 h, k, l 15.fwdarw.15, 15.fwdarw.15, 17.fwdarw.17 Refinement F.sup.2 R[F.sup.2 > 2(F.sup.2)], wR(F.sup.2), S 0.037, 0.075, 1.06 w 1/[.sup.2(F.sub.o.sup.2) + (0.022P).sup.2 + 2.0638P] where P = (F.sub.o.sup.2 + 2F.sub.c.sup.2)/3 No. of reflections 7503 No. of parameters 375 No. of restraints 2 H-site location mixed H-atom treatment H atoms treated by a mixture of independent and constrained refinement (/).sub.max <0.001 >.sub.max, >.sub.min (e .sup.3) 0.95, 0.67
Data collection: Bruker APEX3; cell refinement: Bruker SAINT; data reduction: Bruker SAINT; program(s) used to solve structure: SHELXS97 (Sheldrick 2008); program(s) used to refine structure: SHELXL 2018/3 (Sheldrick, 2015); molecular graphics: Olex2 1.3 (Dolomanov et al., 2009); software used to prepare material for publication: Olex2 1.3 (Dolomanov et al., 2009).

[0215] The molecular structure of crystalline 5-Cl-TET iodide, showing the atom labeling, is shown in FIG. 9.

[0216] FIG. 10 is a simulated x-ray powder diffraction (XRPD) of crystalline 5-Cl-TET iodide from its single crystal data. Crystalline 5-Cl-TET iodide may be characterized by the XRPD peaks at 8.2, 9.1, and 12.1 20.2 2 as well as by an XRPD pattern substantially similar to FIG. 10.

Example 6: Synthesis and Crystallization of 5-bromo-N,N,N-triethyltryptammonium (5-Br-TET) iodide

[0217] 106 mg of 5-Bromo Tryptamine was dissolved in 10 mL of isopropanol, 141 mg of Na.sub.2CO.sub.3 and 0.3 mL of Ethyl Iodide were then added. The mixture was refluxed under nitrogen for 24 hrs. The solvent was stripped off on a rotovap, orange/yellow powder was obtained. The powder was sonicated in 3 mL of THF for 30 minutes then filtered under vacuum yielding 208 mg white powder on the frit. This powder was then sonicated in 20 mL of Acetonitrile then filtered under vacuum. The acetone was then stripped off on the rotovap to obtain a colourless oil product. The oil was recrystallized in acetone resulting in 156 mg of colourless crystals.

[0218] The percent yield was calculated as 77.66%.

[0219] Single crystals suitable for X-ray diffraction was obtained from slow evaporation of Acetone solution.

[0220] .sup.1H NMR (400 MHz, CD.sub.3CN): 9.46 (s, 1H, NH), 7.76 (d, J=1.8 Hz, 1H, ArH), 7.39 (d, J=8.6 Hz, 1H, ArH), 7.29-7.26 (m, 2H, ArH), 3.47-3.29 (m, 8H, CH.sub.2), 3.11-3.07 (m, 2H, CH.sub.2), 1.28 (tt, J=7.2, 1.8 Hz, 9H, CH.sub.3).

[0221] Single crystal data, data collection and structure refinement details of crystalline 5-Br-TET iodide are summarized in Table 13.

TABLE-US-00013 TABLE 13 5-bromo-N,N,N-triethyltryptammonium iodide Chemical formula IC.sub.16H.sub.24BrN.sub.2 M.sub.r 451.18 Crystal system, space group Orthorhombic, P2.sub.12.sub.12.sub.1 Temperature (K) 297 a, b, c () 9.5921 (4), 13.2918 (7), 14.4411 (7) V (.sup.3) 1841.19 (15) Z 4 F(000) 888 D.sub.x (Mg m.sup.3) 1.628 Radiation type M.sub.o K.sub. () 0.71073 () 3.1-26.3 (mm.sup.1) 3.90 Crystal size (mm) 0.24 0.21 0.1 BLOCK Colourless Diffractometer Bruker APEX-II CCD Absorption correction Multi-scan SADABS2016/2 (Bruker, 2016/2) was used for absorption correction. wR2(int) was 0.0677 before and 0.0561 after correction. The Ratio of minimum to maximum transmission is 0.8687. The /2 correction factor is not present. T.sub.min, T.sub.max 0.562, 0.647 No. of measured, independent, and 49433, 3721, 3480 observed [I > 2s(I)] reflections R.sub.int 0.028 .sub.max, .sub.min () 26.4, 2.6 h, k, l 11.fwdarw.11, 16.fwdarw.16, 18.fwdarw.18 Refinement F.sup.2 R[F.sup.2 > 2(F.sup.2)], wR(F.sup.2), S 0.022, 0.049, 1.03 w 1/[.sup.2(F.sub.o.sup.2) + (0.0153P).sup.2 + 1.2042P] where P = (F.sub.o.sup.2 + 2F.sub.c.sup.2)/3 No. of reflections 3721 No. of parameters 188 No. of restraints 0 H-site location mixed H-atom treatment H atoms treated by a mixture of independent and constrained refinement (/).sub.max 0.001 >.sub.max, >.sub.min (e .sup.3) 0.56, 0.52 Absolute Structure Flack x determined using 1456 quotients [(I+) (I)]/ Absolute Structure Parameter [(I+) + (I)] (Parsons, Flack and Wagner, Acta Cryst. B69 (2013) 249-259). Absolute Structure Parameter 0.006 (3)

[0222] Data collection: Bruker APEX3; cell refinement: Bruker SAINT; data reduction: Bruker SAINT; program(s) used to solve structure: SHELXS97 (Sheldrick 2008); program(s) used to refine structure: SHELXL 2018/3 (Sheldrick, 2015); molecular graphics: Olex2 1.3 (Dolomanov et al., 2009); software used to prepare material for publication: Olex2 1.3 (Dolomanov et al., 2009).

[0223] The molecular structure of crystalline 5-Br-TET iodide, showing the atom labeling, is shown in FIG. 11.

[0224] FIG. 12 is a simulated x-ray powder diffraction (XRPD) of crystalline 5-Br-TET iodide from its single crystal data. Crystalline 5-Br-TET iodide may be characterized by the XRPD peaks at 11.1, 12.9, and 20.4 20.2 2 as well as by an XRPD pattern substantially similar to FIG. 12.

Example 7: Synthesis and Crystallization of 5-bromo-N,N,N-tri-n-propyltryptammonium (5-Br-TPT) iodide

[0225] 5-Br-TPT iodide was synthesized via the same procedure used in Example 1. This procedure was repeated using a 5-bromo tryptamine in the presence of excess propyl iodide.

[0226] Single crystal data, data collection and structure refinement details of crystalline 5-Br-TPT iodide are summarized in Table 14.

TABLE-US-00014 TABLE 14 5-bromo-N,N,N-tri-n-propyltryptammonium iodide Chemical formula IC.sub.19H.sub.30BrN.sub.2 M.sub.r 493.26 Crystal system, space group Monoclinic, P2.sub.1/c Temperature (K) 297 a, b, c () 18.2646 (18), 7.6845 (8), 16.2828 (13) () 110.918 (3) V (.sup.3) 2134.7 (4) Z 4 F(000) 984 D.sub.x (Mg m.sup.3) 1.535 Radiation type M.sub.o K.sub. () 0.71073 () 2.9-26.4 (mm.sup.1) 3.37 Crystal size (mm) 0.31 0.24 0.17 BLOCK Yellow Diffractometer Bruker APEX-II CCD Absorption correction Multi-scan SADABS2016/2 (Bruker, 2016/2) was used for absorption correction. wR2(int) was 0.0856 before and 0.0459 after correction. The Ratio of minimum to maximum transmission is 0.6850. The /2 correction factor is not present. T.sub.min, T.sub.max 0.511, 0.745 No. of measured, independent, and 31699, 4330, 3420 observed [I > 2s(I)] reflections R.sub.int 0.035 .sub.max, .sub.min () 26.4, 2.9 h, k, l 22.fwdarw.22, 9.fwdarw.9, 20.fwdarw.19 Refinement F.sup.2 R[F.sup.2 > 2(F.sup.2)], wR(F.sup.2), S 0.035, 0.083, 1.02 w 1/[.sup.2(F.sub.o.sup.2) + (0.0254P).sup.2 + 3.5855P] where P = (F.sub.o.sup.2 + 2F.sub.c.sup.2)/3 No. of reflections 4330 No. of parameters 214 No. of restraints 1 H-site location mixed H-atom treatment H atoms treated by a mixture of independent and constrained refinement (/).sub.max 0.001 >.sub.max, >.sub.min (e .sup.3) 1.15, 0.88
Data collection: Bruker APEX3; cell refinement: Bruker SAINT; data reduction: Bruker SAINT; program(s) used to solve structure: SHELXS97 (Sheldrick 2008); program(s) used to refine structure: SHELXL 2018/3 (Sheldrick, 2015); molecular graphics: Olex2 1.3 (Dolomanov et al., 2009); software used to prepare material for publication: Olex2 1.3 (Dolomanov et al., 2009).

[0227] The molecular structure of crystalline 5-Br-TPT iodide, showing the atom labeling, is shown in FIG. 13.

[0228] FIG. 14 is a simulated x-ray powder diffraction (XRPD) of crystalline 5-Br-TPT iodide from its single crystal data. Crystalline 5-Br-TPT iodide may be characterized by the XRPD peaks at 5.2, 10.4, and 13.1 20.22 as well as by an XRPD pattern substantially similar to FIG. 14.

Example 8: Synthesis and Crystallization of 5-bromo-N,N,N-tri-n-propyltryptammonium (5-Br-TPT) iodide acetonitrile solvate

[0229] 5-Br-TPT iodide acetonitrile solvate was synthesized via the same procedure used in Example 7, except crystals suitable for X-ray diffraction studies were grown from the slow evaporation of an acetone/acetonitrile solution.

[0230] Single crystal data, data collection and structure refinement details of crystalline 5-Br-TPT iodide acetonitrile solvate are summarized in Table 15.

TABLE-US-00015 TABLE 15 5-bromo-N,N,N-tri-n-propyltryptammonium iodide acetonitrile solvate Chemical formula IC.sub.19H.sub.30BrN.sub.2C.sub.2H.sub.3N M.sub.r 534.31 Crystal system, space group Monoclinic, P2.sub.1/c Temperature (K) 297 a, b, c () 11.4346 (5), 14.8646 (5), 14.9080 (6) () 107.269 (1) V (.sup.3) 2419.70 (17) Z 4 F(000) 1072 D.sub.x (Mg m.sup.3) 1.467 Radiation type M.sub.o K.sub. () 0.71073 () 2.9-26.1 (mm.sup.1) 2.98 Crystal size (mm) 0.34 0.25 0.2 BLOCK Colourless Diffractometer Bruker APEX-II CCD Absorption correction Multi-scan SADABS2016/2 (Bruker, 2016/2) was used for absorption correction. wR2(int) was 0.0565 before and 0.0454 after correction. The Ratio of minimum to maximum transmission is 0.8766. The /2 correction factor is not present. T.sub.min, T.sub.max 0.567, 0.647 No. of measured, independent, and 59383, 4956, 3949 observed [I > 2s(I)] reflections R.sub.int 0.036 .sub.max, .sub.min () 26.4, 2.9 h, k, l 14.fwdarw.14, 18.fwdarw.18, 18.fwdarw.18 Refinement F.sup.2 R[F.sup.2 > 2(F.sup.2)], wR(F.sup.2), S 0.029, 0.069, 1.05 w 1/[.sup.2(F.sub.o.sup.2) + (0.0217P).sup.2 + 2.4499P] where P = (F.sub.o.sup.2 + 2F.sub.c.sup.2)/3 No. of reflections 4956 No. of parameters 243 No. of restraints 0 H-site location mixed H-atom treatment H atoms treated by a mixture of independent and constrained refinement (/).sub.max 0.002 >.sub.max, >.sub.min (e .sup.3) 0.80, 0.83
Data collection: Bruker APEX3; cell refinement: Bruker SAINT; data reduction: Bruker SAINT; program(s) used to solve structure: SHELXS97 (Sheldrick 2008); program(s) used to refine structure: SHELXL 2018/3 (Sheldrick, 2015); molecular graphics: Olex2 1.3 (Dolomanov et al., 2009); software used to prepare material for publication: Olex2 1.3 (Dolomanov et al., 2009).

[0231] The molecular structure of crystalline 5-Br-TPT iodide acetonitrile solvate, showing the atom labeling, is shown in FIG. 15.

[0232] FIG. 16 is a simulated x-ray powder diffraction (XRPD) of crystalline 5-Br-TPT iodide acetonitrile solvate from its single crystal data. Crystalline 5-Br-TPT iodide acetonitrile solvate may be characterized by the XRPD peaks at 8.1, 10.0, and 11.9 20.2 2 as well as by an XRPD pattern substantially similar to FIG. 16.

Example 9: Synthesis and Crystallization of 5-bromo-N,N,N-trimethyltryptammonium (5-Br-TMT) iodide

[0233] 5-Br-TMT iodide was synthesized via the same procedure used in Example 7, except this procedure was repeated using a 5-bromo tryptamine in the presence of excess methyl iodide. Crystals suitable for X-ray diffraction studies were grown from the slow evaporation of an acetone/acetonitrile solution.

REFERENCES

[0234] Bradley, R. J. & Johnston, V. S. (1970). Origin and Mechanism of Hallucinations, edited by W. Keup, pp. 333-344. New York: Plenum Press. [0235] Bruker (2018). APEX3, SAINT, and SADABS. Bruker AXS Inc., Madison, Wisconsin, USA. [0236] Cameron, L. P. & Olson, D. E. (2018). ACS Chem. Neurosci. 9, 2344-2357. [0237] Carhart-Harris, R. L. & Goodwin, G. M. (2017). Neuropsychopharmacology, 42, 2105-2113. [0238] Chadeayne, A. R., Pham, D. N. K., Reid, B. G., Golen, J. A. & Manke, D. R. (2020). ACS Omega, https://doi. org/10.1021/acsomega. Oc02208 [0239] Dinis-Oliveira, R. J. (2017). Drug Metab. Rev. 49, 84-91. [0240] Dolomanov, O. V., Bourhis, L. J., Gildea, R. J., Howard, J. A. K. & Puschmann, H. (2009). J. Appl. Cryst. 42, 339-341. Farah, T. (2018). Discover, https://discovermagazine. com/health/beyond-psilocybin-mushrooms-have-lots-of-cool-compounds-scientists-should-study (accessed July, 2020) [0241] J. Gartz, Int. J. Crude Drug Res., 1989, 27, 141-144. [0242] N. Jensen, J. Gartz and H. Laatsch, Planta Med., 2006, 72, 665-666. [0243] Johnson, M. W. & Griffithe, R. R. (2017). Neurotherapeutics 14, 734-740. [0244] Lee, H. M., VanArenkonk, A. M. & Chen, K. K. (1936). J. Pharmacol. Exp. Ther. 56, 446-472. [0245] McKenna, D. J., Repke, D. B., Lo, L. & Peroutka, S. J. (1990). Neuropharmacology, 29, 193-198. [0246] Milne, N., Thomsen, P., Molgaard Knudsen, N., Rubaszka, P., Kristensen, M. & Borodina, I. (2020). Metabolic Engineering, 60, 25-36. [0247] Nichols, D. E. (2012). WIREs Membr. Transp. Signal. 1, 559-579. [0248] Repke, D. B., Grotjahn, D. B. & Shulgin, A. T. (1985). J. Med. Chem. 28, 892-896. [0249] Revell, J. (2020). Vice, https://vice. com/en_in/article-y3zp35/magic-mushroom-paralysis-heres-what-we-know (accessed July, 2020) [0250] Sheldrick, G. M. (2015a). Acta Cryst. A 71, 3-8 [0251] Sheldrick, G. M. (2015b). Acta Cryst. C71, 3-8. [0252] Sherwood, A. M., Halberstadt, A. L., Klein, A. K., McCorvy, J. D., Kaylo, K. W., Kargbo, R. B. & Meisenheimer, P. J. (2020). J. Nat. Prod. 83, 461-467. Wieland, H., Konz, W. & Mittasch, H. (1934). Justus Liebigs Ann. Chem. 513, 1-25.

QUATERNARY TRYPTAMINES AND THEIR THERAPEUTIC USES

Inventors

Cpc classification

Classification Explorer

C07D209/16

CHEMISTRY; METALLURGY

Classification Explorer

A61K45/06

HUMAN NECESSITIES

Classification Explorer

A61K38/44

HUMAN NECESSITIES

Classification Explorer

A61K31/4045

HUMAN NECESSITIES

Classification Explorer

C12P17/165

CHEMISTRY; METALLURGY

International classification

Classification Explorer

C07D209/16

CHEMISTRY; METALLURGY

Classification Explorer

A61K31/4045

HUMAN NECESSITIES

Classification Explorer

A61K38/44

HUMAN NECESSITIES

Classification Explorer

A61K45/06

HUMAN NECESSITIES

Classification Explorer

C12P17/16

CHEMISTRY; METALLURGY

Abstract

Claims

Description